Section |
Name |
Details |
07.04.03 |
Pentosan polysulfate sodium |
Approved for use in line with NICE TA610 |
13.02.01 |
50:50 white soft paraffin and liquid paraffin ointment |
|
05.03.01 |
Abacavir Ziagen® |
Tablet, Oral Solution |
05.03.01 |
Abacavir and Lamivudine Kivexa® |
Tablet |
05.03.01 |
Abacavir and Lamivudine and Zidovudine Trizivir® |
Tablet |
10.01.03 |
Abatacept Orencia® |
injection |
02.09 |
Abciximab |
Injection |
08.03.04.02 |
Abiraterone Zytiga® |
tablet |
04.10.01 |
Acamprosate Campral EC® |
to be initiated and prescribed by commissioned, specialised services. continuation of prescribing needs to be under the advice of commissioned or specialised service |
06.01.02.03 |
Acarbose Glucobay® |
Tablet |
02.08.02 |
Acenocoumarol Sinthrome® |
|
11.06 |
Acetazolamide Diamox® |
250mg Tablets
250mg MR Capsules
500mg Injection (Hospital Initiated)
|
11.08.02 |
Acetycholine 1%, Mannitol 3% Solution |
Acetycholine 1%, Mannitol 3% Solution |
11.08.02 |
Acetylcholine Chloride Miochol-E® |
In 2ml Intraocular |
03.07 |
Acetylcysteine |
|
11.08.01 |
Acetylcysteine 5% with Hypromellose 0.35% |
Acetylcysteine 5% with Hypromellose 0.35% Eye Drops |
05.03.02.01 |
Aciclovir |
Tablet, Suspension
Injection & Infusion
|
13.10.03 |
Aciclovir 5% cream |
|
11.03.03 |
Aciclovir eye ointment 3% Zovirax® |
|
13.05.02 |
Acitretin Capsules |
|
03.01.02 |
Aclidinium Eklira Genuair® |
DPI |
03.01.04 |
Aclidinium and formoterol inhaler Duaklir Genuair ® |
|
01.05.03 |
Adalimumab |
To be in accordance with the associated NICE Technical Appraisals |
10.01.03 |
Adalimumab Humira® |
|
13.05.03 |
Adalimumab |
|
13.06.01 |
Adapalene Differin® |
Gel and cream |
13.06.01 |
Adapalene 0.1% and Benzoyl Peroxide 2.5% gel Epiduo ® |
|
05.03.03.01 |
Adefovir Dipivoxil Hepsera® |
Tablet |
02.03.02 |
Adenosine Adenocor® |
injection |
08.02.02 |
AdoPORT ® Tacrolimus |
NHSE funded indication are usually Hospital Only
|
03.04.03 |
Adrenaline / epinephrine EpiPen® & Jext® |
|
02.07.03 |
Adrenaline / Epinephrine 1 in 10,000 (dilute) |
|
08.02.02 |
Advagraf ® |
NHSE funded indication are usually Hospital Only
|
08.01.05 |
Afatinib Giotrif® |
|
11.08.02 |
Aflibercept |
Injection |
20 |
Ajmaline |
50mg/10ml Injection
Consultant Cardiologist only for diagnosis of Brugada syndrome |
05.05.01 |
Albendazole |
unlicensed
Tablet 400mg (unlicensed import, some products are chewable)
Specialist recommendation (discuss specific therapies and investigations with a Microbiologist or an Infectious Disease specialist) |
08.01.05 |
Alectinib Alecensa® |
CAPSULE |
08.02.03 |
Alemtuzumab Lemtrada® |
infusion |
06.06.02 |
Alendronic Acid |
Tablets 10mg, 70mg
(including 70 mg effervescent Tablets for PEG/NG tube patient administration) |
09.06.04 |
Alfacalcidol One-Alpha® |
250 nanogram, 1 microgram capules
2 microgram/1mL oral drops |
15.01.04.03 |
Alfentanil |
Injection
500 microgram/ mL, 2mL injection
High strength: 5mg/mL, 1mL injection ICU only |
04.07.02 |
Alfentanyl |
Injection |
07.04.01 |
Alfuzosin |
Tablet, Tablet m/r |
03.04.01 |
Alimemazine Vallergan® |
|
02.14 |
Alirocumab Praluent® |
Subcutaneous Injection |
13.05.01 |
Alitretinoin Toctino® |
NICE TA177:Alitretinoin for the treatment of severe chronic hand eczema |
10.01.04 |
Allopurinol |
tablets |
06.01.02.03 |
Alogliptin Vipidia▼® |
Tablet |
07.04.05 |
Alprostadil Caverject® |
Injection, Dual chamber
Intracavernosal injection 10 micrograms, 20 micrograms
- specialist initiation.
|
07.04.05 |
Alprostadil Viridal® Duo |
Intracavernosal injection 10 micrograms, 20 micrograms, 40 micrograms |
07.04.05 |
Alprostadil MUSE® |
Urethral application 125 micrograms, 250 micrograms, 500 micrograms, 1mg |
02.10.02 |
Alteplase Actilyse® |
injection |
01.01.01 |
Aluminimum Hydroxide |
|
04.09.01 |
Amantadine |
|
05.01.04 |
Amikacin |
Injection |
02.02.03 |
Amiloride Hydrochloride |
|
03.01.03 |
Aminophylline |
Tablet MR - Restricted for existing patients only, new patients to start on theophylline.
injection
|
02.03.02 |
Amiodarone |
Tablets
Injection is hospital only
|
04.02.01 |
Amisulpride |
Tablet
Oral Solution |
04.03.01 |
Amitriptyline |
Tablets
Syrup |
02.06.02 |
Amlodipine |
Tablets |
05.01.01.03 |
Amoxicillin |
Capsules
Syrup
Sachets
|
05.01.01.03 |
Amoxicillin |
injection |
05.02 |
Amphotericin Abelcet ® AmBisome ® Fungizone ® |
Infusion |
09.01.04 |
Anagrelide Xagrid® |
|
08.03.04.01 |
Anastrozole |
1mg Tablet |
05.02.04 |
Anidulafungin Ecalta® |
infusion |
11.04.02 |
Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® |
Eye Drops |
01.07.01 |
Anusol ® |
ointment cream suppositories |
01.07.02 |
Anusol-HC |
|
02.08.02 |
Apixaban Eliquis® |
Tablets |
04.09.01 |
Apomorphine |
|
11.08.02 |
Apraclonidine |
Eye Drop 0.5%
Eye Drops 1% Single Dose Units |
10.01.03 |
Apremilast (Ortezla® ) |
Tablet - approved in line with NICE TA419 and NICE TA433 |
13.05.03 |
Apremilast Otezla® |
|
04.06 |
Aprepitant Emend® |
Use as per HYCCN Network
|
13.02.01 |
AproDerm ® Colloidal Oat Cream |
For use when a paraffin-free emollient is required |
01.06.03 |
Arachis Oil |
enema |
04.02.01 |
Aripiprazole |
Tablets, Orodispersible tablets,Oral solution Injection 7.5mg/ml(secondary care only) |
08.01.05 |
Arsenic Trioxide Trisenox® |
Infusion |
05.04.01 |
Artemether with lumefantrine Riamet® |
tablets (treatment of uncomplicated Falciparum) |
09.06.03 |
Ascorbic Acid Vitamin C |
|
01.01.01 |
Asilone |
Restricted use for palliative care only |
02.09 |
Aspirin |
Soluble Tablets |
05.03.01 |
Atazanavir Reyataz® |
Capsule |
02.04 |
Atenolol |
Tablets, Syrup
Injection
|
08.02.04 |
Atezolizumab (Tecentriq®) |
Concentrate for solution for infusion |
04.04 |
Atomoxetine Strattera® |
Atomoxetine Capsules |
02.12 |
Atorvastatin |
|
07.01.03 |
Atosiban Tractocile ® |
Injection
Atosiban Injection 7.5mg/ml, 0.9ml vial.
Atosiban Concentrate for Intravenous Infusion 7.5mg/ml, 5ml vial. |
15.01.05 |
Atracurium besilate |
Injection -requires storage in refrigerator
|
11.05 |
Atropine |
Eye Drops 0.5%
Eye Drops 1%
Eye Ointment 1%
Minims 1% |
15.01.03 |
Atropine sulfate |
600 microgram/mL
1mg/10mL pre-filled syringe |
09.01.04 |
Avatrombopag |
|
08.02.04 |
Avelumab (Bavencio®) |
Concentrate for solution for infusion |
08.02.04 |
Axicabtagene ciloleuce (Yescarta®) |
|
08.01.05 |
Axitinib Inlyta® |
Tablet |
08.01.03 |
Azacitidine Vidaza® |
Injection |
01.05.03 |
Azathioprine |
Tablets |
08.02.01 |
Azathioprine |
Tablets 25mg, 50mg |
10.01.03 |
Azathioprine |
tablet |
05.01.05 |
Azithromycin |
Capsules, Suspension |
05.01.02.03 |
Aztreonam |
Injection
Group three restricted
Microbiologist authorisation only |
09.03 |
Babiven TPN Solution |
|
10.02.02 |
Baclofen |
syrup
tablets |
11.06 |
Balanced Salt Solution |
Preservative Free 15ml
Preservative Free 500ml |
01.05.01 |
Balsalazide colazide |
capsules |
10.01.03 |
Baricitinib (Olumiant®) |
tablet |
08.02.02 |
Basiliximab Simulect® |
Injection |
03.02 |
Beclometasone Qvar®kelhale® |
|
03.02 |
Beclometasone Clenil Modulite® |
|
03.02 |
Beclometasone and formoterol Fostair® |
|
03.02 |
Beclometasone and formoterol Fostair NEXThaler® |
|
03.02 |
Beclometasone, Formeterol and Glycopyrronium Trimbow® |
Triple dose inhaler available as a pressurised metered dose inhaler delivering a solution with a nominal dose per actuation of 87 micrograms beclometasone dipropionate, 5 micrograms formoterol fumarate dihydrate and 9 micrograms glycopyrronium |
03.04.02 |
Bee and Wasp Allergen Extracts Pharmalgen® |
|
10.01 |
Belimumab Benlysta® |
|
08.01.01 |
Bendamustine |
infusion |
02.02.01 |
Bendroflumethiazide |
|
05.01.01.01 |
Benzathine Penicillin |
|
13.06.01 |
Benzoyl Peroxide |
|
13.06.01 |
Benzoyl Peroxide and Clindamycin Gel Duac Once Daily |
|
05.01.01.01 |
Benzylpenicillin |
Injection |
03.05.02 |
Beractant Survanta® |
peadiatrics |
13.09 |
Betadine® |
|
04.06 |
Betahistine Dihydrochloride |
Tablets |
06.03.02 |
Betamethasone |
soluble tablets, Injection
Betnesol ® |
10.01.02.02 |
Betamethasone |
|
11.04.01 |
Betamethasone |
Eye Drops 0.1%
Eye Ointment 0.1% |
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic® |
|
13.04 |
Betamethasone (as Valerate) 0.025% |
|
13.04 |
Betamethasone (as Valerate) 0.1% Betnovate® |
|
13.04 |
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® |
|
13.04 |
Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® |
|
11.04.01 |
Bethamethasone with Neomycin |
Eye Drops
Eye Ointment |
08.01.05 |
Bevacizumab Avastin® |
Infusion |
11.08.02 |
Bevacizumab Intravitreal Syringe Avastin® |
unlicensed
5mg/0.2ml Intravitreal Syringe |
08.01.05 |
Bexarotene Targretin® |
|
02.12 |
Bezafibrate |
Tablets and Modified Release Tablets |
08.03.04.02 |
Bicalutamide |
50mg and 150mg tablets |
11.06 |
Bimatoprost |
Eye Drops 100mcg/ml
Eye Drops 300mcg/ml UDVs for Preservative Sensitivity |
11.06 |
Bimatoprost with Timolol |
Bimatoprost 300mcg/ml, Timolol 5mg/ml Eyr drops (UDVs for Preservative Sensitivity) |
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
Vial, Cartridge, Prefilled pen |
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix 25 |
lispro 25% / Lispro Protamine 75%
KwikPen, 3mL |
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix 50 |
Lispro 50%, Protamine 75%
KwikPen, 3mL cartridge |
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
Vial Cartridge, Kwikpen |
01.06.02 |
Bisacodyl |
Tablets, suppositories |
02.04 |
Bisoprolol |
Tablets
First line use for all patients with systolic LV dysfunction
|
02.08.01 |
Bivalirudin Angiox® |
|
08.01.02 |
Bleomycin |
injection |
08.02 |
Blinatumomab Blincyto® |
Infusion |
05.03.03.02 |
Boceprevir Victrelis® |
capsule |
08.01.05 |
Bortezomib Velcade® |
|
08.01.05 |
Bosutinib Bosulif® |
Tablet |
04.07.04.02 |
Botulinum Toxin Type A botox® |
Injection Vials |
04.09.03 |
Botulinum Toxin Type A Botox® |
injection |
08.01.05 |
Brentuximab vedotin Adcetris® |
infusion |
11.06 |
Brimonidine |
Eye Drops 0.2% |
11.06 |
Brimonidine 0.2% with Timolol 0.5% |
Eye Drops Brimonidine 0.2% with Timolol 0.5% |
11.06 |
Brinzolamide |
Eye Drops 1% |
11.06 |
Brinzolamide 1% with Timolol 0.5% |
Eye Drops Brinzolamide 1%, Timolol 5mg/ml |
11.06 |
Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza® |
Brinzolamide 10mg/ml & brimonidine 2mg/ml Eye Drops |
04.08.01 |
Brivaracetam Briviact® |
Tablets
Liquid |
11.04.02 |
Bromfenac |
Eye Drops 0.09% |
06.07.01 |
Bromocriptine Parlodel® |
Tablets |
01.05.02 |
Budesonide Entocort® |
Modified Release Capsules |
03.02 |
Budesonide |
Easyhaler, dry powder inhalation
Nebules -acute treatment of croup
|
03.02 |
Budesonide and formoterol Fobumix Easyhaler® |
easyhaler |
03.02 |
Budesonide and formoterol Symbicort® |
|
03.02 |
Budesonide and formoterol DuoResp Spiromax® |
|
02.02.02 |
Bumetanide |
Tablet, Liquid
Injection
|
15.02 |
Bupivacaine and Adrenaline |
Injection |
15.02 |
Bupivacaine Hydrochloride |
Injection, infusion |
04.07.02 |
Buprenorphine BuTrans® patch |
|
04.07.02 |
Buprenorphine Transtec® patch |
|
04.10.03 |
Buprenorphine Subutex® |
Sublingual Tablets
To be commenced by specialist service only and prescribing must be in collaboration with the advice from substance misuse services. |
04.10.03 |
Buprenorphine and Naloxone Suboxone® |
Tablets
To be commenced by specialist service only and prescribing must be in collaboration with the advice from the substance misuse services |
06.07.02 |
Buserelin |
Nasal Spray |
08.03.04.02 |
Buserelin |
|
04.01.02 |
Buspirone Hydrochloride |
tablets |
08.01.01 |
Busulfan |
tablet, infusion |
03.04.03 |
C1 Esterase Inhibitor Berinert® |
|
08.01.05 |
Cabazitaxel Jevtana® |
infusion |
06.07.01 |
Cabergoline |
500 microgram tablets |
08.01.05 |
Cabozantinib Cabometyx® |
Tablet |
13.05.02 |
Calcipotriol Ointment |
|
13.05.02 |
Calcipotriol Scalp Application |
|
13.05.02 |
Calcipotriol with Betamethasone Dovobet ® Enstillar® |
|
06.06.01 |
Calcitonin (salmon) / Salcatonin |
Injection 400u in 2ml, 100 units/ml, 1ml amp |
09.06.04 |
Calcium and Ergocalciferol Tablet |
calcium lactate 300mg, calcium phosphate 150mg and ergocalciferol 10 microgram |
09.05.01.01 |
Calcium carbonate tablets Calcichew®, Calcichew® Forte, Cacit®, |
1.25g calcium carbonate:
Chewable tablets: Calcichew® 500mg tablets
Effervescent tablets: Cacit® tablets
1.5g calcium carbonate:
Chewable tablets: Adcal 1500mg chewable
2.5g calcium carbonate
Chewable tablets: Calcichew® Forte 1g tablets
|
09.06.04 |
Calcium Carbonate with Colecalciferol |
- Calcium carbonate 750mg/colecalciferol 5 microgram e.g. Adcal-D3 750mg/200unit caplets
- Calcium carbonate 1.25g/colecalciferol 10 microgram chewable tablets e.g. Calcichew D3 Forte chewable
- Calcium carbonate 1.5g/colecalciferol 10 microgram e.g. Evacal D3 chewable tablets, Accrete D3 tablets,
|
08.01 |
Calcium Folinate |
Tablet, injection |
09.05.01.01 |
Calcium Sandoz Syrup |
|
06.01.02.03 |
Canagliflozin Invokana▼® |
Tablet |
02.05.05.02 |
Candesartan |
Tablets |
13.09 |
Capasal ® |
|
13.05.02 |
Capasal Therapeutic Shampoo |
|
08.01.03 |
Capecitabine Xeloda® |
Tablet |
10.03.02 |
Capsaicin Qutenza® |
capsaicin cream |
02.05.05.01 |
Captopril |
Tablets
Oral Solution |
04.08.01 |
Carbamazepine |
Syrup
Tablets
Modified Release tablets |
06.02.02 |
Carbimazole |
Tablets |
03.07 |
Carbocisteine |
Capsules, Liquid |
11.08.01 |
Carbomers |
980 Eye Drops
980 Single-dose units |
08.01.05 |
Carboplatin |
Injection |
07.01.01 |
Carboprost |
Injection |
08.01.05 |
Carfilzomib Kyprolis® |
Powder for infusion |
11.08.01 |
Carmellose Sodium |
Single Dose Units 0.5%, 1% |
11.08.01 |
Carmellose Sodium |
0.5% Single dose unit
1% Single dose unit |
08.01.01 |
Carmustine BiCNU® |
Injection |
08.01.01 |
Carmustine Gliadel® |
implant |
11.06 |
Carteolol Teoptic® |
Eye Drops 1%
Eye Drops 2% |
02.04 |
Carvedilol |
Tablets |
05.02.04 |
Caspofungin Cancidas® |
|
07.04.04 |
Catheter Patency Solutions |
Chlorhexidine
Chlorhexidine Uro-Tainer 0.02% |
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
13.02.02 |
Cavilon® Cream |
|
05.01.02.01 |
Cefalexin |
Capsules, Syrup, Tablets
restricted to indication. To be used in accordance with the local antibitic guidance and guidance from health protection agency |
05.01.02.01 |
Cefixime |
Tablets |
05.01.02.01 |
Cefotaxime |
Injection - for Meningitis and Neonatal Use Only |
05.01.02.01 |
Ceftazidime |
Injection |
05.01.02.01 |
Ceftobiprole |
Injection |
05.01.02.01 |
Ceftriaxone |
Injection
For pelvic inflammatory disease
|
05.01.02.01 |
Cefuroxime |
Injection |
11.03.01 |
Cefuroxime |
unlicensed
5% Eye Drops
50mg Intra-cameral Injection |
10.01.01 |
Celecoxib Celebrex® |
Capsule Cox-2 Inhibitor - osteoarthritis, rheumatoid arthritis Second line in patients unable to tolerate standard NSAID's.
|
02.04 |
Celiprolol Hydrochloride |
|
08.01 |
Cemiplimab Libtayo® |
Infusion |
08.01.05 |
Ceritinib Zykadia |
Capsule |
10.01.03 |
Certolizumab Pegol Cimzia® |
|
03.04.01 |
Cetirizine |
|
13.02.01 |
Cetraben ® Lotion |
|
08.01.05 |
Cetuximab Erbitux® |
Injection |
08.01.01 |
Chlorambucil |
Tablet |
05.01.07 |
Chloramphenicol |
Capsule, Injection
Microbiology Approval is required |
11.03.01 |
Chloramphenicol |
Eye Drops 0.5%
Eye Ointment 1%
Minims 0.5% |
04.01.02 |
Chlordiazepoxide |
capsule |
11.03.02 |
Chlorhexidine |
unlicensed
0.02% Eye Drops |
05.04.01 |
Chloroquine |
Tablet, Syrup
Injection
For the treatment of malaria. Should not be prescribed for malaria prophylaxis on the NHS. Patients should obtain a supply on private prescription or purchase a supply "over the counter" as appropriate |
02.02.01 |
Chlorothiazide |
Suspension 250mg/5ml for paediatric use only. Available as an unlicensed product
|
03.04.01 |
Chlorphenamine |
|
04.02.01 |
Chlorpromazine |
Tablet, Oral solution, Suppository, Injection |
06.05.01 |
Chorionic Gonadotrophin Pregnyl® Choragon® |
Injection |
01.05.03 |
Ciclosporin Neoral |
Neoral 25mg, 50mg & 100mg capsules
Neoral 100mg/ml oral solution 50ml
Deximune 25mg, 50mg and 100mg capsules - to be used by dermatology only |
08.02.02 |
Ciclosporin |
Capsules,
Oral, Solution
Injection
NHSE funded indication are usually Hospital Only
|
11.03.01 |
Ciclosporin |
Eye Drops 0.1% |
11.04.02 |
Ciclosporin |
Eye Drops 1% (As per NICE TA369)
|
13.05.03 |
Ciclosporin |
Due to differences in bioavailability, patients must remain on the same brand of immunosuppressant. |
01.03.01 |
Cimetidine |
Indication for painful bladder only |
09.05.01.02 |
Cinacalcet Mimpara® |
|
04.06 |
Cinnarizine |
|
05.01.12 |
Ciprofloxacin |
'Restricted by Indication'
Tablet, Suspension
Injections 'prescribed in hospital only'
|
11.03.01 |
Ciprofloxacin |
Eye Drops 0.3% |
15.01.05 |
Cisatracurium |
Injection
|
08.01.05 |
Cisplatin |
Injection |
04.03.03 |
Citalopram |
tablets
Oral Drops |
01.06.05 |
Citramag ® |
|
08.01.03 |
Cladribine |
Infusion |
08.01.03 |
Cladribine Mavenclad® |
Tablet |
05.01.05 |
Clarithromycin |
Injection, Tablets, Suspension, Sachets |
05.01.05 |
Clarithromycin Klaricid ® |
for Lower repsirtory tract infections |
05.01.06 |
Clindamycin |
Use of Clindamycin is restricted by indication. Consult Antimicrobial Guidance before use
Capsules
Injection
Suspension - Hospital Paediatric Use Only unlicensed
|
07.02.02 |
Clindamycin Dalacin® |
Used for bacterial vaginosis |
04.08.01 |
Clobazam |
Tablets
Oral Suspension |
13.04 |
Clobetasol propionate 0.05% |
|
13.04 |
Clobetasone butyrate 0.05% |
|
13.04 |
Clobetasone butyrate, Nystatin, Oxytetracycline calcium Trimovate ® |
|
08.01.03 |
Clofarabine Evoltra® |
Intravenous infusion |
06.05.01 |
Clomifene Citrate Clomid® |
Tablet |
04.03.01 |
Clomipramine |
Caspsule |
04.02.03 |
Clonazepam |
tablets |
02.05.02 |
Clonidine Catapres® |
Tablets
Injection
|
04.07.04.02 |
Clonidine Hydrochloride |
Tablets |
02.09 |
Clopidogrel |
Tablet |
07.02.02 |
Clotrimazole |
Cream 2% - please consult antibiotic formulary advice
500mg pessaries (stat treatment)
Canestan "Pessary Combi" for Primary care use only
|
13.10.02 |
Clotrimazole cream |
|
04.02.01 |
Clozapine |
tablet |
13.05.02 |
Coal Tar 10% Carbo-Dome® |
|
02.02.04 |
Co-amilofruse (furosemide and amiloride) |
Tablet |
05.01.01.03 |
Co-Amoxiclav |
Tablets, Dispersible Tablets, Suspension
To be prescribed in accordance with local antimicrobial guidance and guidance from health protection agency |
05.01.01.03 |
Co-Amoxiclav |
Injection |
04.09.01 |
Co-Beneldopa Madopar®CR |
Capsules |
04.09.01 |
Co-Beneldopa Madopar® |
(Benserazide/Levodopa) Capsules, MR Capsules, Dispersible tablets |
05.03.01 |
Cobicistat Tybost® |
Tablet |
11.07 |
Cocaine |
Eye Drops 4%, 10ml |
04.09.01 |
Co-Careldopa Half Sinemet ®CR |
(Carbidopa/Levodopa) Tablets, MR Tablets |
04.09.01 |
Co-Careldopa and Entacapone |
Tablets |
13.06.02 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) |
|
01.06.02 |
Co-danthrusate |
Capsules
To be used to treat terminally ill patients only |
04.07.02 |
Codeine |
Tablets |
03.09.01 |
Codeine Linctus |
|
01.04.02 |
Codeine Phosphate |
Tablets |
04.07.02 |
Codeine Phosphate |
|
10.01.04 |
Colchicine |
tablets |
09.06.04 |
Colecalciferol |
Maintenance and preventative treatments should be recommended to be purchased OTC. Therefore no solid dosage form under 800iu should be prescribed.
Capsules
800iu (20 microgram) e.g. Invita D3 800unit capsules
20,000iu e.g. Hux D3 20,000 unit capsules
50,000iu e.g. Invita D3 50,000 unit capsules
Oral Drops
10,000iu/mL e.g. Thorens 10,000iu/mL (10mL pack)
|
01.09.02 |
Colesevelam |
625mg Tablets |
02.12 |
Colestyramine |
Sachets |
01.09.02 |
Colestyramine powder |
|
05.01.07 |
Colistimethate ® colomycin |
Injection Microbiologist approval required in all cases |
05.01.07 |
Colistimethate for nebulisation Colobreathe® |
Capsule - dry powder for inhalation For the management of chronic pulmonary infections caused by P.aeruginosa in patients with cystic fibrosis (CF) |
05.01.07 |
Colistimethate for nebulisation Promixin® |
Nebule "Restricted by Indication" |
10.03.01 |
Collagenase Xiapex® |
Injection |
01.01.01 |
Co-magaldrox Maalox® |
Use with caution in severe renal impairment as aluminium and magnesium may accumulate.
Suitable for patients with hepatic or cardiac failure, as it has low sodium content and is sugar free. |
06.04.01.01 |
Combined continuous HRT tablet Kliofem, Kliovance, Femoston Conti, Premique |
Kliofem® tablet (estradiol/Norethisterone)- no bleed |
06.04.01.01 |
Combined cyclical HRT patch Evorel® Sequi, Evorel® Conti |
Transdermal patch 20micrograms, 50micrograms, 75micrograms & 100micrograms |
07.03.01 |
Combined Hormonal Contraceptives Microgynon 30 ED® |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
07.03.01 |
Combined Hormonal Contraceptives TriNovum® |
Ethinylestradiol 35micrograms and Norethisterone 500 micrograms, 750 micrograms and 1000micrograms. |
07.03.01 |
Combined Hormonal Contraceptives Femodene® ED |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
09.02.02.01 |
Compound Sodium Lactate Intravenous Infusion |
|
03.04.03 |
Conestat Alfa Ruconest® |
For the treatment of hereditary angioedema in the emergency care setting. |
06.04.01.01 |
Conjugated Oestrogen tablet Elleste-Solo, Premarin |
Conjugated Oestrogens ( Premarin) 0.625mg, 1,25mg tablets |
13.02.02 |
Conotrane® |
|
05.01.08 |
Co-trimoxazole Septrin® |
Tablet 480mg, Suspension
Injection
|
13.08.02 |
Covermark ® |
ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo) |
08.01.05 |
Crisantaspase Erwinase® |
|
08.01.05 |
Crizotinib Xalkori® |
Capsule |
13.03 |
Crotamiton Eurax® |
|
13.03 |
Crotamiton + Hydrocortisone Eurax HC® |
|
09.01.02 |
Cyanocobalamin |
|
04.06 |
Cyclizine Valoid® |
Tablets
Injection |
11.05 |
Cyclopentolate |
Eye Drops 0.5%
Eye Drops 1%
Minims 0.5%
Minims 1% |
08.01.01 |
Cyclophosphamide |
Tablet, Injection |
08.03.04.02 |
Cyproterone |
Tablet |
06.04.02 |
Cyproterone Acetate |
Tablets |
08.01.03 |
Cytarabine DepoCyte® |
lipid formulation for intrathecal use |
02.08.02 |
Dabigatran Pradaxa® |
Capsules |
08.01.05 |
Dabrafenib Tafinlar® |
capsule |
08.01.05 |
Dacarbazine |
Injection |
05.03.03.02 |
Daclatasvir Daklinza® |
Tablet |
08.02.02 |
Daclizumab Zenapax® |
|
08.01.05 |
Dacomitinib Vizimpro®) |
Tablet |
08.01.02 |
Dactinomycin Cosmegen Lyovac® |
injection |
06.07.02 |
Danazol Danol® |
Capsules |
10.02.02 |
Dantrolene |
capsules |
15.01.08 |
Dantrolene |
Injection |
06.01.02.03 |
Dapagliflozin Forxiga▼® |
Tablet |
05.01.10 |
Dapsone |
tablet |
05.01.07 |
Daptomycin |
Injection
Microbiology approval required |
08.02.04 |
Daratumumab (Darzalex®) |
Solution for infusion |
09.01.03 |
Darbepoetin Alfa Aranesp® |
|
06.04.02 |
Darolutamide |
|
05.03.03.02 |
Dasabuvir Exviera® |
Tablet |
08.01.05 |
Dasatinib Sprycel® |
Tablet
Powder for oral Suspension |
08.01.02 |
Daunorubicin DaunoXome® |
injection |
08.01.02 |
Daunorubicin 44mg and Cytarabine 100mg Vyxeos® |
Injection |
08.03.04.02 |
Degarelix Firmagon® |
injection |
09.06.07 |
DEKAs Plus Soft gels |
For use in CF patients only as recommended by the specialist centre |
05.01.03 |
Demeclocycline |
Capsules
Limited clinical use in context of antibiotic. Sometimes indicated for endocrine indications such as SIADH. Hence warranting restrited use
|
06.06.02 |
Denosumab XGEVA® |
70mg/ml Injection |
06.06.02 |
Denosumab Prolia® |
60mg/ml Injection |
13.08.02 |
Dermacolor ® |
ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo) |
09.01.03 |
Desferrioxamine Mesilate |
|
15.01.02 |
Desflurane Suprane® |
240mL bottle for vaporisation |
06.05.02 |
Desmopressin |
Tablets 200 micrograms
For nocturnal enuresis,
Any pituitary condition the status should be designated as amber- please refer to chapter 7 for enuresis indication |
06.05.02 |
Desmopressin DDAVP® Octim® |
Injection 4 micrograms/ml, 1ml & 15 micrograms/ml, 1ml |
06.05.02 |
Desmopressin |
Sublingual tablets |
06.05.02 |
Desmopressin Desmospray® |
Nasal spray 10 micrograms/dose, 5ml |
07.03.02.01 |
Desogestrel Cerazette®, Cerelle® |
Tablet |
06.03.02 |
Dexamethasone |
Tablets Injection Dexamethasone elixir 2mg/5ml |
10.01.02.02 |
Dexamethasone |
|
11.04.01 |
Dexamethasone |
Eye Drops
0.1 Single Dose Eye Drops Preservative Free
700mcg Intravitreal Impant (as per NICE TA301)
|
11.04.01 |
Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® |
Eye Drops
Eye Ointment |
04.04 |
Dexamfetamine |
|
04.07.02 |
Diamorphine |
Tablets, Injection
Diamorphine hydrochloride (Ayendi ) 720microgram/actuation Nasal Spray, CD
*Please see information regarding current shortage: Patient Information *Patient information – diamorphine *
Further information regarding Diamorphine Shortage (mainly applicable for Secondary Care prescribing) Unfortunately Accord have advised that there has been a further delay to their resupply date for diamorphine 5mg and 10mg injection and they are now expecting stock to be available during the week commencing 10th September. Wockhardt’s position remains unchanged, so please can all hospitals continue with current management plans as per previous communications in email chain below until the middle of September. There have been no changes to the supply position for the alternatives, so please refer to below communication for information about this. We will communicate further information about the recovery plan in early September.
|
04.01.02 |
Diazepam |
Tablets Oral solution
Diazepam is a high risk injectable medicine as identified by the NPSA patient safety alert 20
|
04.08.02 |
Diazepam |
Injection, emulsion injection
Diazepam is a high risk injectable medicine as identified by the NPSA patient safety alert 20 |
04.08.02 |
Diazepam |
Rectal Tubes |
04.08.03 |
Diazepam |
rectal tubes |
10.02.02 |
Diazepam |
Oral solution, tablets |
06.01.04 |
Diazoxide |
50 mg Tablet, oral solution (250mg/5mL)
Approved indications:
Insulinoma and tumour induced hypoglycaemia
Post gastric bypass hypoglycaemia causing syncope |
10.01.01 |
Diclofenac |
Tablets |
10.01.01 |
Diclofenac |
Suppositories Injection
Not recommended as a first line NSAID of choice due to small cardiac risks with diclofenac |
10.03.02 |
Diclofenac |
Diclofenac Sodium Gel 1.16%. |
13.08.01 |
Diclofenac Solaraze® |
|
11.08.02 |
Diclofenac Sodium Voltarol® Ophtha |
0.1% Single Dose Units |
05.03.01 |
Didanosine Videx® |
Tablet
Capsule |
05.05.06 |
Diethylcarbamazine |
unlicensed
Tablets |
02.01.01 |
Digoxin |
Bioavailabilites are approximately: Injection 100%, Liquid 80%, Tablets 70%.
Digoxin 500micrograms/ml injection
Digoxin 100micrograms/ml injection. Hospital, Paediatrics Only (SP)
|
04.07.02 |
Dihydrocodeine |
Tablets
Injection
oral Liquid
|
05.04.02 |
Diloxanide |
|
02.06.02 |
Diltiazem |
Diltiazem MR (12hour) Tablets, Capsules. Prescribe by brand
Diltiazem XL (24 hour) Capsules. Prescribe by brand |
01.07.04 |
Diltiazem Cream 2% |
cream |
08.02.04 |
Dimethyl fumarate Tecfidera® |
|
08.02.04 |
Dimethyl fumarate Skilarence |
for treating moderate to severe plaque psoriasis
|
13.10.04 |
Dimeticone lotion |
|
07.01.01 |
Dinoprostone |
Injection MR pessaries (Propess) Vaginal gel
1st choice for induction of labour as per NLAG induction guidelines
|
08.02.04 |
Dinutuximab (Qarziba®) |
|
13.09 |
Diprosone® 0.05% Lotion |
|
02.09 |
Dipyridamole and Aspirin |
Modified Release Capsule |
02.09 |
Dipyridamole MR |
Capsule
Dipyridamole Suspension
Dipyridamole injection
|
11.09 |
Disodium Edetate |
unlicensed
0.37% Solution 20ml
4% Solution 200ml |
06.06.02 |
Disodium Etidronate Didronel PMO® |
200mg Tablets |
06.06.02 |
Disodium Pamidronate |
Injection 15mg, 90mg vial. Hospital Only |
02.03.02 |
Disopyramide |
capsules
MR tablets |
04.10.01 |
Disulfiram Antabuse® |
to be initiated and prescribed by commissioned, specialised services. continuation of prescribing needs to be under the advice of commissioned or specialised service |
13.05.02 |
Dithranol Cream |
|
13.05.02 |
Dithranol Paste |
|
02.07.01 |
Dobutamine |
injection |
08.01.05 |
Docetaxel Taxotere® |
Injection |
01.06.02 |
Docusate Sodium |
Capsules Oral Solution |
05.03.01 |
Dolutegravir tivicay ® |
Tablet |
05.03.01 |
Dolutegravir, abacavir & lamivudine Triumeq® |
Tablet |
04.06 |
Domperidone |
Tablets |
04.11 |
Donepezil Aricept® |
Usually commenced by memory specialist then followed by GP |
02.07.01 |
Dopamine |
injection |
02.07.01 |
Dopexamine |
10mg/ml injection |
03.07 |
Dornase Alfa |
|
11.06 |
Dorzolomide |
Eye Drops 2% |
11.06 |
Dorzolomide 2% with Timolol 0.5% |
Dorzolomide 2%, Timolol 0.5% Eye Drops |
04.03.01 |
Dosulepin |
tablet
Capsule |
13.02.01 |
DoubleBase ® gel |
|
03.05.01 |
Doxapram Dopram® |
|
15.01.07 |
Doxapram Dopram® |
20mg/mL, 5mL injection |
02.05.04 |
Doxazosin |
Tablets |
07.04.01 |
Doxazosin |
Tablet |
08.01.02 |
Doxorubicin |
Injection |
08.01.02 |
Doxorubicin Caelyx® |
Concentrate for intravenous infusion |
05.01.03 |
Doxycycline |
Capsules
Dispersible Tablets |
02.03.02 |
Dronedarone Multaq® |
Tablets |
06.01.02.03 |
Dulaglutide Trulicity ® |
Injection
To be used in accordance with the Diabetes Pathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation. |
04.03.04 |
Duloxetine Cymbalta® |
|
13.05.03 |
Dupilumab |
|
08.02.04 |
Durvalumab (Imfinzi® ) |
concentrate for solution for infusion |
06.04.02 |
Dutasteride Avodart® |
Capsules |
06.04.01.02 |
Dydrogesterone |
Tablets |
02.08.02 |
Edoxaban Lixiana® |
Tablets
Edoxaban is the preferred DOAC for stroke prevention in NVAF. This includes use in patients who have switched from warfarin.
Please consult the DOAC guideline below |
10.02.01 |
Edrophonium Chloride |
|
05.03.01 |
Efavirenz Sustiva® |
Capsule, Tablet |
13.09 |
Eflornithine Vaniqa® |
|
05.03.03.02 |
Elbasvir/Grazoprevir Zepatier® |
|
09.01.04 |
Eltrombopag Revolade® |
|
01.04.02 |
Eluxadoline |
Tablet
To be used in Accordance with NICE TA 471 |
06.01.02.03 |
Empagliflozin Jardiance▼® |
Tablet |
05.03.01 |
Emtricitabine Emtriva® |
Capsule, Oral Solution |
05.03.01 |
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera® |
Tablet |
13.02.01 |
Emulsifying ointment |
|
02.05.05.01 |
Enalapril |
Tablets |
02.01.02 |
Enoximone Perfan® |
|
04.09.01 |
Entacapone Comtess® |
|
05.03.03.01 |
Entecavir Baraclude® |
Tablet Use in accordance with NICE guidance |
08.01.05 |
Entrectinib |
|
08.03.04.02 |
Enzalutamide Xtandi® |
capsule |
02.07.02 |
Ephedrine |
injection |
13.02.01 |
Epimax ® |
|
08.01.02 |
Epirubicin |
Injection |
02.02.03 |
Eplerenone |
Tablet
SECOND CHOICE
Second line aldosterone antagonist if spironolactone is not tolerated for NYHA class II heart failure
Second Line agent if Spironolactone is not tolerated for use within the licenced indication, of stable post MI patient with left ventricular dysfunction and clinical evidence of heart failure in line with NICE guidance.
|
09.01.03 |
Epoetin alfa Eprex® |
|
09.01.03 |
Epoetin beta NeoRecormon® |
|
02.09 |
Eptifibatide Integrilin® |
INJECTION |
09.06.04 |
Ergocalciferol |
capsules, oral solution, injection
|
07.01.01 |
Ergometrine Maleate |
500micrograms/ml Injection |
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
Injection |
04.07.04.01 |
Ergotamine Tartrate |
Tablets |
08.01.05 |
Eribulin Halaven® |
Injection |
08.01.05 |
Erlotinib Tarceva® |
Tablets |
08.01.05 |
Erlotinib Tarceva® |
Tablets |
05.01.02.02 |
Ertapenem |
solution for infusion
Microbiologist Approval required in all cases |
06.01.02.03 |
Ertugliflozin Steglatro® |
Tablets |
05.01.05 |
Erythromycin |
Talets
Use in pregnancy or if there is a known intolerance to clarithromycin
|
05.01.05 |
Erythromycin |
Lactobionate Injection - Hospital Only - GI motility agent only |
05.01.05 |
Erythromycin |
Erythromycin ethyl succinate mixture |
13.06.01 |
Erythromycin 40mg/ Zine acetate 12mg/mL topical solution Zineryt® |
|
04.03.03 |
Escitalopram Cipralex® |
Tablets |
02.04 |
Esmolol |
Injection/Infusion |
01.03.05 |
Esomeprazole |
Tablets |
06.04.01.01 |
Estradiol with Noresthisterone |
Elleste-Duet®- tablet 1mg and 2mg Femoston 1/10 and 2/10 tablet |
08.01.01 |
Estramustine Phosphate Estracyt® |
|
10.01.03 |
Etanercept Benepali® |
subcutaneous injection |
10.01.03 |
Etanercept Enbrel® |
subcutaneous injection |
13.05.03 |
Etanercept |
|
05.01.09 |
Ethambutol |
tablet
unlicensed - Ethambutol Liquid. Consultant Paediatrician Only (unlicenced & specials) |
06.04.01.01 |
Ethinylestradiol |
2microgram tablets Secondary care, Paediatrician initiated only
10micrograms, 50micrograms, 1mg tablets
|
07.03.01 |
Ethinylestradiol / levonorgestrel phased pill Logynon® |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg Yasmin® |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
07.03.01 |
Ethinylestradiol 30 mcg / levonorgestrel 150 mcg Ovranette® Rigevidon® |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®, Marvelon® |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
07.03.01 |
Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique® |
Not formulary within secondary care during inpatient stay, please encourage patients to use their own supply.
Can be prescribed for outpatient clinics for secondary care |
04.08.01 |
Ethosuximide |
Oral Solution |
15.02 |
Ethyl Chloride Cryogesic® Spray |
|
15.01.01 |
Etomidate |
20mg in 10mL injection |
07.03.02.02 |
Etonorgestrel Implanon® |
68mg Implant (Nexplanon). Primary Care & Sexual Health Only |
08.01.04 |
Etoposide Etopophos® |
Capsule, Infusion |
05.03.01 |
Etravirine Intelence® |
Tablet |
08.01.05 |
Everolimus Votubia® |
Tablet
Dispersible tablet |
08.01.05 |
Everolimus Afinitor® |
Tablets |
02.14 |
Evolocumab Repatha® |
Subcutaneous Injection |
08.03.04.01 |
Exemestane |
Tablets 25mg |
06.01.02.03 |
Exenatide prolonged release Bydureon▼® |
Injection m/r Bydureon= once weekly formulation
To be used in accordance with the Diabetes Pathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation |
02.12 |
Ezetimibe Ezetrol® |
To be used in accordance with associated NICE technical appraisal |
02.11 |
Factor VIIa (Recombinant) Novo 7® |
|
05.03.02.01 |
Famciclovir Famvir® |
Tablet |
06.01.01.01 |
Fast Acting Insulin Aspart Fiasp® |
Injection
Must be initiated by specialist only.
To be prescribed by brand only |
10.01.04 |
Febuxostat Adenuric® |
tablets |
04.07.02 |
Fentanyl Instanyl® nasal spray |
Nasal Spray – Lindsey Lodge Hospice Only CD |
04.07.02 |
Fentanyl |
Patches |
04.07.02 |
Fentanyl |
Injection |
15.01.04.03 |
Fentanyl |
Injection
500 microgram/mL, 2mL injection, 10mL injection |
04.07.02 |
Fentanyl Nasal Spray PecFent® |
|
04.07.02 |
Fentanyl sublingual tablets Abstral® |
Only for prescribing in primary care once stable dose has been established, following titration by Lindsey Lodge Hospice. |
09.01.01.01 |
Ferrous Fumarate |
|
09.01.01.01 |
Ferrous Gluconate |
|
09.01.01.01 |
Ferrous Sulfate |
|
03.04.01 |
Fexofenadine |
|
11.08.02 |
Fibrin Sealant Tisseel |
|
05.01.07 |
Fidaxomicin |
200mg Tablets - Requires Microbiologist authorisation
Suitable for Primary care to prescribe provided there is authorisation from a microbiologist |
05.01.07 |
Fidaxomicin Dificlir® |
|
09.01.06 |
Filgrastim Zarzio®, |
prefilled syringe 30million units/0.5mL prefilled syringe 48million units/0.5mL |
06.04.02 |
Finasteride |
Tablets |
08.02.04 |
Fingolimod |
|
02.03.02 |
Flecainide |
Tablet and Syrup
|
01.06.05 |
Fleet Phospho-soda ® |
Oral Solution |
05.01.01.02 |
Flucloxacillin |
Capsules
Syrup |
05.01.01.02 |
Flucloxacillin |
Injection |
05.02 |
Fluconazole |
Injection, Infusion |
05.02 |
Fluconazole Diflucan® |
Capsule, Suspension |
07.02.02 |
Fluconazole |
Tablet, Capsule |
08.01.03 |
Fludarabine Phosphate Fludara® |
Tablet, Injection |
06.03.01 |
Fludrocortisone |
Tablets
if prescribed for postural hypotension
|
15.01.07 |
Flumazenil |
100 microgram/ mL, 5mL injection |
11.04.01 |
Fluocinolone intravitreal implant Iluvien® |
As per NICE TA301 |
11.08.02 |
Fluorescein |
1% Minims
2% Minims
20 Injections (Hospital Consultant Only)
|
11.04.01 |
Fluorometholone FML® |
Eye Drops 0.1% |
08.01.03 |
Fluorouracil |
|
08.01.03 |
Fluorouracil |
cream
For dermatology indications |
13.08.01 |
Fluorouracil 5% cream Efudix® |
|
04.03.03 |
Fluoxetine |
Capsules |
04.02.01 |
Flupentixol Depixol® |
tablet |
04.02.02 |
Flupentixol Decanoate Depixol® |
Depot Injection |
04.02.02 |
Flupentixol Decanoate Depixol® Conc. |
Depot Injection |
04.02.02 |
Fluphenazine Decanoate |
depot injection |
08.03.04.02 |
Flutamide |
Tablets |
03.02 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
|
03.02 |
Fluticasone furoate, umeclidinium & vilanterol (as trifenatate) trelegy ® |
Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder (pre-dispensed) contains the following:
Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 92 micrograms fluticasone furoate, 65 micrograms umeclidinium bromide equivalent to 55 micrograms umeclidinium and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 74.2 micrograms umeclidinium bromide equivalent to 62.5 micrograms umeclidinium and 25 micrograms vilanterol (as trifenatate). |
03.02 |
Fluticasone propionate and formoterol Flutiform® |
children between 12-18 where sirdupla is not licenced |
03.02 |
Fluticasone propionate and salmeterol AirFluSal Forspiro® |
|
03.02 |
Fluticasone propionate and salmeterol Sirdupla®, Seretide® |
Seretide 50 Evohaler * Paediatric use only
Seretide Evohaler and Accuhaler. Restricted to use in asthma not to be used as new initiation for COPD
|
09.01.02 |
Folic Acid |
|
02.08.01 |
Fondaparinux Arixtra® |
For Acute Coronary Syndrome |
03.01.01.01 |
Formoterol |
Turbohaler
- Long-acting beta-agonist
- Formoterol Easyhaler® preferred as more cost effective
|
05.03.01 |
Fosamprenavir Telzir® |
Tablet, Oral Suspension |
05.01.07 |
Fosfomycin |
3g Oral Sachets
Not be used first line and must be used in accordance with culture and sensitivity results.
For treatment resistant UTI licenced for women, doses change as per gender
Injection ( Unlicensed )
|
04.07.04.02 |
Fremanezumab |
|
08.03.04.01 |
Fulvestrant Faslodex® |
Injection |
02.02.02 |
Furosemide |
Injection. IV doses of 40mg or 80mg can be slow bolused. Larger doses must be infused at a max rate of 4mg/min
|
11.03.01 |
Fusidic Acid |
Eye Drops 1% |
13.10.01.02 |
Fusidic Acid 2% Fucidin® |
|
04.08.01 |
Gabapentin |
Capsules
From April 2019 gabapentin will be reclassified as class C controlled substance. Prescriptions will need to be physically signed by doctors; electronic copies will not be accepted by pharmacists - the total quantity will need to be written on the prescription in both words and figures and pharmacists will need to dispense the drugs within 28 days of the prescription being written |
04.11 |
Galantamine Galsya® XL |
Tablet
Modified Release Capsules |
04.07.04.02 |
Galcanezumab |
|
05.03.02.02 |
Ganciclovir Cymevene® |
Infusion |
11.03.03 |
Ganciclovir 0.15% ophthalmic gel Virgan® |
|
01.01.02 |
Gastrocote |
Tablets |
01.01.02 |
Gaviscon Infant ® |
Oral Powder
For peadiatric use only |
08.01.05 |
Gefitinib Iressa® |
Tablet |
08.01.03 |
Gemcitabine Gemzar® |
injection |
08.02.03 |
Gemtuzumab ozogamicin |
injection |
05.01.04 |
Gentamicin |
Injection |
11.03.01 |
Gentamicin |
unlicensed
1.5% Eye Drops |
11.03.01 |
Gentamicin |
Eye Drops 0.3% |
06.07.02 |
Gestrinone |
Capsules 2.5mg |
08.01.05 |
Gilteritinib |
|
08.02.04 |
Glatiramer Acetate Copaxone® |
injection |
05.03.03.02 |
Glecaprevir and Pibrentasvir Maviret® |
Tablet |
06.01.02.01 |
Gliclazide |
Tablets, Modified release tablets
Non modified release formulation are first choice |
06.01.04 |
Glucagon GlucaGen® HypoKit |
Injection, Tablets , Drink ( e.g. lucozade drink) |
06.01.04 |
GlucoGel ® |
Dextrose Gel,
|
09.02.02.01 |
Glucose 10% Intravenous |
infusion 250mL, 500mL, 1000mL |
09.02.02.01 |
Glucose 2.5% + Sodium Chloride 0.45% Intravenous |
infusion 500mL |
09.02.02.01 |
Glucose 20% Intravenous |
infusion 500mL |
09.02.02.01 |
Glucose 5% + Sodium Chloride 0.9% Intravenous |
infusion 500mL, 1000mL |
09.02.02.01 |
Glucose 5% Intravenous |
infusion 50ml, 100mL, 250mL, 500mL, 1000mL |
09.02.02.01 |
Glucose 50% Intravenous |
injection 50mL |
06.01.06 |
Glucose Monitoring System FreeStyle Libre ® |
FreeStyle Libre® is a flash glucose monitoring (Flash GM) system which monitors glucose levels using interstitial fluid levels rather than capillary blood glucose from finger prick testing
All prescribing of freestyle libre should be carried out in line with the agreed prescribing statement below
https://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2019/08/Prescribing-Arrangements-for-Flash-Glucose-Monitoring-Final-2.pdf |
11.06 |
Glycerin |
50% Eye Drops unlicensed
BP Syrup, licensed |
11.06 |
Glycerin |
50% Eye Drops unlicensed
BP Syrup, licensed |
01.06.02 |
Glycerol |
suppositories |
02.06.01 |
Glyceryl Trinitrate |
Available as S/L Tablet, Spray
Injection
Patches
|
01.07.04 |
Glyceryl Trinitrate 0.4% |
Ointment |
07.04.04 |
Glycine |
Irrigation solution 1.5% |
03.01.04 |
Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler® |
|
03.01.02 |
Glycopyrronium Seebri breezhaler® |
|
15.01.03 |
Glycopyrronium Bromide |
200 microgram in 1mL injection
For use in palliative care on advice of the palliative care team. |
15.01.03 |
Glycopyrronium Bromide and Neostigmine Metisulfate |
Glycopyrronium 500 micrograms & Neostigmine 2.5mg/ml injection |
01.05.03 |
Golimumab |
to be used in accordance with NICE TA329 |
10.01.03 |
Golimumab Simponi® |
|
06.05.01 |
Gonadorelin HRF® |
Injection |
06.07.02 |
Goserelin Zoladex® |
Injection Injection 3.6mg, 10.8mg. |
08.03.04.01 |
Goserelin Zoladex® |
Injection 3.6mg, 10.8mg |
08.03.04.02 |
Goserelin Zoladex® |
3.6mg Injection |
08.03.04.02 |
Goserelin Zoladex® LA |
10.8mg Injection |
04.06 |
Granisetron |
Injection
Tablets
Consultant Initiated Only and Restricted Hospice Use |
04.06 |
Granisetron transdermal patch Sancuso® |
Patches
Consultant Initiated Only and Restricted Hospice Use |
03.04.02 |
Grass and Tree Pollen Extract Pollinex® |
Subcutaneous Injection by Immunologist Only |
02.05.03 |
Guanethidine Monosulphate Ismelin® |
injection |
04.04 |
Guanfacine |
|
13.05.03 |
Guselkumab |
|
04.02.01 |
Haloperidol |
Capsule Tablet Oral liquid
haloperidol solution for injection |
04.02.02 |
Haloperidol Haldol Decanoate® |
Depot Injection |
02.08.01 |
Heparin |
Injection |
02.08.01 |
Heparin |
Flush Injection |
11.05 |
Homatropine |
Minims 2% |
10.01 |
Hyaluronic acid Hyalgan® |
|
10.03.01 |
Hyaluronidase Hyalase® |
|
02.05.01 |
Hydralazine |
Tablets
Injection
|
01.05.02 |
Hydrocortisone Colifoam® |
Foam Enema
Colifoam |
06.03.02 |
Hydrocortisone |
10mg tablets, 20mg tablets |
06.03.02 |
Hydrocortisone |
Suspension 5mg/5ml Paediatrician Initiated Only |
11.04.01 |
Hydrocortisone |
Eye Ointment 2.5% |
13.04 |
Hydrocortisone |
|
06.03.02 |
Hydrocortisone acetate |
Injection 100mg |
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
|
13.04 |
Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone® |
|
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
|
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® |
|
13.11.06 |
Hydrogen Peroxide Cream |
|
13.11.06 |
Hydrogen Peroxide Solution BP |
|
13.02.01 |
Hydrous ointment |
|
09.01.02 |
Hydroxocobalamin |
|
08.01.05 |
Hydroxycarbamide |
Capsule |
10.01.03 |
Hydroxychloroquine |
tablet |
11.08.01 |
Hydroxypropyl Guar Systane® |
Ultra
Ultra UD
Balance
Gel |
01.02 |
Hyoscine Butylbromide |
Tablets,
Injection - only green for use in Palliative care only
|
04.06 |
Hyoscine Hydrobromide |
Tablets
Patches
|
15.01.03 |
Hyoscine Hydrobromide |
400microgram in 1mL injection |
11.08.01 |
Hypromellose |
0.3% Eye Drops
0.5% Eye Drops
1% Eye Drops |
11.08.01 |
Hypromellose 0.3% with Dextran 70 0.1% |
Hypromellose 0.3% with Dextran 70 0.1% Eye Drops |
06.06.02 |
Ibandronic Acid |
50mg Tablets. Hospital Initiated
See HYCCN Guidelines |
06.06.02 |
Ibandronic Acid |
150mg Tablets |
06.06.02 |
Ibandronic Acid injection |
3mg Injection Post-menopausal Osteoporosis |
08.01.05 |
Ibrutinib Imbruvica® |
Capsule, Tablet |
10.01.01 |
Ibuprofen |
Tablet, Suspension |
10.03.02 |
Ibuprofen gel |
topical gel |
03.04.03 |
Icatibant Firazyr® |
For the treatment of hereditary angioedema in the emergency care setting. |
13.05.01 |
Ichthammol |
|
13.05.01 |
Ichthammol |
|
08.01.02 |
Idarubicin Zavedos® |
Capsule, injection |
02.08 |
Idarucizumab Praxbind® |
Injection. For reversal of dabigatran anticoagulation only. Not suitable for Anti Xa Agents |
08.01.05 |
Idelalisib Zydelig® |
Not recommended for use by NICE in NICE TA604 |
08.01.01 |
Ifosfamide Mitoxana® |
|
02.05.01 |
Iloprost injection |
|
08.01.05 |
Imatinib Gilvec® |
tablet |
05.01.02.02 |
Imipenem with Cilastatin |
Injection
Group 3 restricted.
Microbiology approval is required in all cases |
04.03.01 |
Imipramine |
tablet |
13.08.01 |
Imiquimod 3.75% cream Zyclara® |
|
08.02.04 |
Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) (Kymriah®) |
|
02.02.01 |
Indapamide |
2.5mg Tablets |
11.08.02 |
Indocyanine Green Dye |
|
10.01.01 |
Indometacin |
Capsules, MR Capsules |
02.05.04 |
Indoramin |
Tablets |
01.05.03 |
Infliximab |
|
10.01.03 |
Infliximab |
|
13.05.03 |
Infliximab |
|
08.01 |
Inotuzumab ozogamicin Besponsa® |
infusion |
06.01.01.01 |
Insulin Humulin® S |
Vial, KwikPen, 3mL cartridge, 100unils/mL |
06.01.01.01 |
Insulin Actrapid® |
Vial
100units/mL |
06.01.01.01 |
Insulin 500 units in 1mL Humulin R® |
unlicensed product
Named patient only |
06.01.01.01 |
Insulin Aspart NovoRapid® |
Vial, Cartridge, Pre-filled pen (FlexPen, FlexTouch) |
06.01.01.02 |
Insulin degludec Tresiba® |
In light of adhering towards the integrated Diabetes pathway the AMBER status only applies if the Diabetologist has provided a written confirmation ( via email/ or letter etc) to a General Practitioner stating the appropriateness of initiating the prescribing of Tresiba.
General Practitioner are therefore permitted to prescribe this medication provided that the suitability of initiating this product must be identified by a specialist/ diabetologist. |
06.01.02.03 |
Insulin degludec and liraglutide Xultophy® |
Pre-filled pen
|
06.01.01.02 |
Insulin Detemir Levemir® |
Cartridge, Prefilled pen (FlexPen, InnoLet) Long-acting insulin analogues (LAIAs) have no advantages over human isophane insulin in effects on HbA1c levels. |
06.01.01.02 |
Insulin Glargine Lantus® |
Vial, Cartridge for ClikSTAR Prefilled pen - Solostar® Long-acting insulin analogues (LAIAs) |
06.01.01.02 |
Insulin Glargine Toujeo® |
In light of adhering towards the integrated Diabetes pathway the AMBER status only applies if the Diabetologist has provided a written confirmation ( via email/ or letter etc) to a General Practitioner stating the appropriateness of initiating the prescribing of Toujeo.
General Practitioner are therefore permitted to prescribe this medication provided that the suitability of initiating this product must be identified by a specialist/ diabetologist. |
06.01.01.02 |
Insulin Glargine biosimilar |
100 units/mL - Cartridge and KwikPen prefilled pen |
06.01.01.01 |
Insulin Glulisine Apidra® |
Vial, 3mL cartridge, solostar |
06.01.01.01 |
Insulin Lispro Humalog® |
Vial, KwikPen, 3ml cartridge, 100units/mL |
08.02.04 |
Interferon Alfa |
|
08.02.04 |
Interferon Alfa Roferon-A® |
|
08.02.04 |
Interferon Beta Avonex® |
Injection |
08.02.04 |
Interferon beta Extavia® |
|
08.02.04 |
Interferon Beta Rebif® |
injection |
08.02.04 |
Interferon Beta Betaferon® |
Injection |
09.03 |
Intralipid |
10%, 20%, 30% |
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
Intra-uterine system |
06.02.02 |
Iodine and Iodide |
Aqueous Iodine BP Syn:Lugol's solution |
08.01.05 |
Ipilimumab Yervoy® |
Concentrate for intravenous infusion |
03.01.02 |
Ipratropium Bromide |
Short-acting antimuscarinic Inhaler, Nebules Should only be prescribed for those patients with COPD in whom salbutamol is not tolerated or ineffective. It should not be used in combination with salbutamol. For those patients requiring regular antimuscarinuc therapy tiotropium is the prefered choice |
02.05.05.02 |
Irbesartan |
Tablets |
08.01.05 |
Irinotecan Hydrochloride |
Infusion |
09.01.01.01 |
Iron and Folic Acid Pregaday® |
|
09.01.01.02 |
Iron Dextran CosmoFer® |
|
09.01.01.02 |
Iron Isomaltoside Monofer® |
|
09.01.01.02 |
Iron Sucrose Venofer® |
|
08.01.05 |
Isatuximab |
|
15.01.02 |
Isoflurane |
250mL bottle for vaporisation |
05.01.09 |
Isoniazid |
Tablet, Injection Elixir 50mg/5ml - Unlicensed |
06.01.01.02 |
Isophane Insulin Insulatard® |
Vial, Cartridge, Prefilled InnoLet |
06.01.01.02 |
Isophane Insulin Humulin® I |
Vial, Cartridge, Prefilled pen (KwikPen) |
02.06.01 |
Isosorbide Dinitrate Injection- Isoket® |
|
02.06.01 |
Isosorbide Mononitrate |
Tablets
including Long acting, once daily preparation |
13.06.01 |
Isotretinoin |
|
01.06.01 |
Ispaghula Husk |
Granules |
05.02 |
Itraconazole |
Capsules, Liquid |
02.06.03 |
Ivabradine |
Tablets
Specialist Initation only for two indications :
1) Angina
Cardiology specialist initiation only in line with NICE Clinical Guidance on stable angina for patients who remain symptomatic despite maximal doses of other anti-anginal medication.
2) Heart Failure
In line with NICE TA 267. Ivabradine is an option for treating people with chronic heart failure who meet the following criteria :
- with NYHA class II to IV stable chronic heart failure with systolic dysfunction and - who are in sinus rhythm with a heart rate of 75 bpm or more and - who are given ivabradine in combination with standard therapy including beta-blocker therapy, ACE inhibitors and aldosterone antagonists, or when beta-blocker therapy is contraindicated or not tolerated and - with a left ventricular ejection fraction of 35% or less. |
05.05.06 |
Ivermectin |
unlicensed
Tablets |
13.06 |
Ivermectin cream Soolantra® |
|
08.01.05 |
Ixazomib Ninlaro® |
Capsule |
13.05.03 |
Ixekizumab |
|
13.08.02 |
Keromask ® |
ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo) |
15.01.01 |
Ketamine |
10mg/mL 20mL injection |
05.02 |
Ketoconazole Nizoral® |
Shampoo |
11.08.02 |
Ketorolac Trometamol |
Eye Drops 0.5% |
03.04.01 |
Ketotifen |
|
01.06.05 |
Klean-Prep ® |
KleanPrep Vanilla for Patients sensitive to citrus Flavourings and paediatrics |
02.04 |
Labetalol |
Tablets
Injection
|
09.04.01 |
LaBiNIC® Probiotic |
|
04.08.01 |
Lacosamide Vimpat ® |
Tablets
Solution for infusion
|
01.06.04 |
Lactulose |
Liquid |
05.03.01 |
Lamivudine Epivir® |
Tablet Oral Solution |
05.03.01 |
Lamivudine Zeffix® |
Tablet |
04.02.03 |
Lamotrigine |
Tablets
Dispersible Tablets |
03.04.03 |
Lanadelumab |
|
08.03.04.03 |
Lanreotide |
Injection - Prefilled syringe |
01.03.05 |
Lansoprazole |
Capsules
Orodispersible tablets restricted for use in patients with swallowing difficulties or who are on enteral tube feeding.
|
08.01.05 |
Larotrectinib |
|
11.06 |
Latanoprost |
Eye Drops 50mcg/ml (UDVs for Preservative Sensitivity) |
11.06 |
Latanoprost 0.005% with Timolol 0.5% |
Latanoprost 50mcg, Timolol 5mg/ml |
05.03.03.02 |
Ledipasvir and Sofosbuvir Harvoni® |
Tablet |
10.01.03 |
Leflunomide |
Tablet |
08.02.04 |
Lenalidomide |
Capsule |
09.01.06 |
Lenograstim Granocyte® |
|
08.01.05 |
Lenvatinib Lenvima® and Kisplyx® |
Capsule
To be prescribed by brand |
02.08.01 |
Lepirudin |
|
02.06.02 |
Lercanidipine |
|
05.03.02.02 |
Letermovir |
|
08.03.04.01 |
Letrozole |
Tablet |
06.07.02 |
Leuprorelin Prostap® |
Injection 3.75mg, 11.25mg |
08.03.04.02 |
Leuprorelin Acetate Prostap® SR |
3.75mg Injection |
08.03.04.02 |
Leuprorelin Acetate Prostap® 3 |
11.25mg Injection |
05.05.02 |
Levamisole |
unlicensed
Unlicenced Tablet |
04.08.01 |
Levetiracetam |
Tablets
Oral Solution |
05.01.12 |
Levofloxacin |
Tablet
Levofloxacin Infusion 500mg/100ml restricted use only
|
13.03 |
Levomenthol Menthoderm®, Dermacool®, Arjun |
Licensed products should be used where possible |
04.06 |
Levomepromazine |
Tablet
Injection |
07.03.05 |
Levonogrestrel Levonelle® 1500 |
Tablets |
06.02.01 |
Levothyroxine |
Tablets |
02.03.02 |
Lidocaine |
injection |
15.02 |
Lidocaine |
|
15.02 |
Lidocaine |
|
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
15.02 |
Lidocaine 4% cream LMX4 |
|
15.02 |
Lidocaine 5% and Phenylephrine 0.5% |
|
15.02 |
Lidocaine hydrochloride |
0.5%, 1%, 2% injection in 2mL, 5mL and 10mL ampoules |
11.07 |
Lidocaine hydrochloride 4%, Fluorescein Sodium 0.25% |
Lidocaine hydrochloride 4%, Fluorescein Sodium 0.25% Minims |
15.02 |
Lidocaine with Adrenaline Xylocaine® |
Lidocaine 1% and 2% with adrenaline 1 in 200,000 |
15.02 |
Lidocaine2% with Chlorhexidine 0.25% Instillagel® |
|
01.06.07 |
Linaclotide Constella® |
Consultant Initiation only as per constipation pathway |
06.01.02.03 |
Linagliptin Trajenta▼® |
DPP-4 inhibitor approved for use in patients with severe renal or hepatic impairment |
05.01.07 |
Linezolid |
Tablet, Injection Microbiologist approval required in all cases |
06.02.01 |
Liothyronine |
Tablets, Injection |
06.01.02.03 |
Liraglutide Victoza® |
Injection
To be used in accordance with Diabetespathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation. |
04.04 |
Lisdexamfetamine Elvanse® |
Capsules |
02.05.05.01 |
Lisinopril |
Tablets |
04.02.03 |
Lithium Carbonate Priadel® |
Tablet MR |
04.02.03 |
Lithium Carbonate Essential Pharma |
Tablet MR
|
04.02.03 |
Lithium Carbonate Liskonum® |
Tablet MR |
04.02.03 |
Lithium Citrate Priadel® |
liquid
Liquid 520mg (approx 5.4mmol Li+) in 5ml. |
06.01.02.03 |
Lixisenatide Lyxumia▼® |
Injection
For use as an adjunct to existing oral hypoglycaemic and/or insulin therapy in type 2 diabetes mellitus (DM) where glycaemic control is inadequate
To be used in accordance with the Diabetes Pathway. Initiation of GLP 1 agonists analogues to be carried out by prescribers trained in insulin initiation |
04.03.01 |
Lofepramine |
Tablet,
Oral Solution |
08.01.01 |
Lomustine |
|
01.04.02 |
Loperamide |
capsules
syrup
immodium instant melts for stoma patients only
|
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
Tablet Liquid |
03.04.01 |
Loratadine |
|
04.01.02 |
Lorazepam |
tablets |
04.08.02 |
Lorazepam |
Injection |
15.01.04.01 |
Lorazepam |
Injection |
08.01.05 |
Lorlatinib |
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
02.05.05.02 |
Losartan |
Tablet |
11.04.01 |
Loteprednol |
Eye Drops 0.5% |
01.06.07 |
Lubiprostone Amitiza® |
To be used in accordance with NICE TA318 |
04.02.01 |
Lurasidone Latuda® |
Tablet
For use in RDASH Only, but requires clinicians to complete a prior approval form before prescribing of the drug is considered |
09.01.04 |
Lusutrombopag |
|
05.01.03 |
Lymecycline Tetralysal® 300 |
Capsules |
01.01.01 |
Maalox Plus |
|
01.06.04 |
Macrogol |
Sachets |
01.06.05 |
Macrogols Moviprep® |
Sachets |
13.10.05 |
Magnesium Sulphate Paste BP |
|
01.01.01 |
Magnesium Trisilicate |
|
13.10.04 |
Malathion 0.5% liquid |
|
02.02.05 |
Mannitol |
Hospital Only |
11.06 |
Mannitol |
20% Infusion |
03.07 |
Mannitol inhalation Bronchitol ® |
|
05.03.01 |
Maraviroc Celsentri® |
Tablet
Oral Solution |
05.05.01 |
Mebendazole |
Tablets Suspension |
01.02 |
Mebeverine |
|
03.07 |
Mecysteine Visclair® |
Tablets |
06.04.01.02 |
Medroxyprogesterone Acetate Provera® |
Tablets |
07.03.02.02 |
Medroxyprogesterone Acetate Depo-Provera® |
150 mg/ml PFS. Primary Care & Sexual Health Only |
08.03.02 |
Medroxyprogesterone Acetate Provera® |
Tablet
injection
for treatment of oncology indications
|
10.01.01 |
Mefenamic Acid |
|
05.04.01 |
Mefloquine Lariam® |
|
04.01.01 |
Melatonin Circadin® |
modified release tablet |
04.01.01 |
Melatonin Paediatrics |
unlicensed Oral solution - unlicenced preparation
unlicensed 1mg/ml oral preparation (colonis) is NOT suitable for paediatric prescribing please refer to product characteristics for further information.
unlicensed Standard release tabets -unlicenced preparation
|
10.01.01 |
Meloxicam |
Tablets |
08.01.01 |
Melphalan |
tablet, Injection |
04.11 |
Memantine Ebixa® |
Tablet, orodispersible tablet and solution |
09.06.06 |
Menadiol Sodium Phosphate |
|
05.04.04 |
Mepacrine Hydrochloride |
|
03.04.02 |
Mepolizumab Nucala® |
|
01.05.03 |
Mercaptopurine |
Tablets |
08.01.03 |
Mercaptopurine |
tablet, suspension |
05.01.02.02 |
Meropenem |
Injection
Group 2 restricted due to 9 permitted indications.
To be used in accordance with antimicrobial guidance and health protection agency guidance |
01.05.01 |
Mesalazine Octasa |
Modified Release Tablets
Octasa is the first choice formulation for all newly diagnosed patients as it is more cost-effective than Asacol. |
01.05.01 |
Mesalazine Asacol® |
1g/ application foam enema, gastro-resistant tablet, suppository,
not first choice for commencing new patients on mesalazine. Asacol is mainly reserved for patients who are stable on asacol formulations. |
01.05.01 |
Mesalazine Pentasa® |
modified release granules, modified release tablets, suppositories, enema |
01.05.01 |
Mesalazine Salofalk® |
Liquid enema, foam enema |
01.05.01 |
Mesalazine Mezavant® XL |
Mezavant XL ( Modified release tablets) |
08.01 |
Mesna |
Tablet, injection |
02.07.02 |
Metaraminol |
Injection |
06.01.02.02 |
Metformin Modified Release tablet® SR |
|
06.01.02.02 |
Metformin |
Tablet, sachets, Oral Liquid |
04.07.02 |
Methadone |
tablets |
04.10.03 |
Methadone |
To be commenced by the specialist service only and prescribing must be in collaboration with the advice from the substance misuse services. |
05.01.13 |
Methenamine Hippurate Hiprex® |
Tablets – Following Urologist recommendation only
Features in Primary care document |
01.05.03 |
Methotrexate |
2.5mg tablets |
08.01.03 |
Methotrexate |
Injection |
10.01.03 |
Methotrexate |
Tablets
|
10.01.03 |
Methotrexate Metoject® |
Subcutaneous injecton is currently Hospital Only |
04.07 |
Methoxyflurane Penthrox® |
3ml +Inhaler + ac chamber
for use in Emergency Care Centres only |
13.05.02 |
Methoxypsoralen |
|
01.06.01 |
Methycellulose |
Tablets |
02.05.02 |
Methyldopa |
tablets |
01.06.06 |
Methylnaltrexone Relistor® |
|
04.04 |
Methylphenidate |
Prescribe generically, unless a brand is necessary |
04.04 |
Methylphenidate Hydrochloride Ritalin® |
MR Tablets
Concerta XL, Matoride XL, Xenidate XL
Note different release properties between each brand. Prescribe by brand where necessary. Specialist Initiated Only. |
04.04 |
Methylphenidate Hydrochloride Equasym® XL |
MR Capsules
Equasym XL,
Medikinet XL |
06.03.02 |
Methylprednisolone |
500mg injection 1g Vial
Methylprednisolone 100mg tablets, Rahabilitation services and Opthalmic surgery only |
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
Injection 40mg in 1mL Injection 80mg in 2mL |
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® with Lidocaine |
|
04.06 |
Metoclopramide |
Tablets
Injection |
02.02.01 |
Metolazone |
Tablet was discontinued March 2012.
For patients in whom bendroflumethiazide is not suitable, an unlicensed import may be available for use by secondary care
|
02.04 |
Metoprolol |
Tablets |
05.04.02 |
Metronidazole |
Tablet, Suspension, Suppository
Infusion
|
07.02.02 |
Metronidazole Zidoval® |
Vaginal gel 0.75% |
13.06 |
Metronidazole 0.75% |
|
13.10.01.02 |
Metronidazole 0.75% |
|
06.07.03 |
Metyrapone Metopirone® |
|
07.02.02 |
Miconazole Gyno-Daktarin® |
Intravaginal cream
Vaginal capsule |
13.10.02 |
Miconazole cream Daktarin® |
|
15.01.04.01 |
Midazolam |
Injection |
04.08.02 |
Midazolam hydrochloride |
Injection.
Solution for injection/infusion |
04.08.02 |
Midazolam Hydrochloride Buccolam® |
oromucosal solution |
04.08.02 |
Midazolam Maleate |
10mg Oromucosal Solution |
02.07.02 |
Midodrine |
Consultant initiation only when fludrocortisone ineffective for orthostatic hypotension. |
08.01.05 |
Midostaurin Rydapt® |
Capsule |
08.02.04 |
Mifamurtide Mepact® |
Intravenous Infusion |
07.01.02 |
Mifepristone Mifegyne® |
Tablet
To be used in adherence with the Termination of pregnancy guideline |
02.01.02 |
Milrinone |
Injection |
02.05.01 |
Minoxidil |
Tablets |
07.04.02 |
Mirabegron Betmiga® |
Tablet m/r |
04.03.04 |
Mirtazapine |
Tablet
Orodisperible tablet
Oral solution |
01.03.04 |
Misoprostol |
Tablets |
07.01.01 |
Misoprostol |
Tablets |
08.01.02 |
Mitomycin |
Injection, bladder instillation |
08.01.02 |
Mitoxantrone Onkotrone® |
Infusion |
08.01.02 |
Mitoxantrone (Mitozantrone) |
Infusion |
15.01.05 |
Mivacurium |
Injection |
04.03.02 |
Moclobemide |
Tablets |
04.04 |
Modafinil Provigil® |
Tablets |
13.04 |
Mometasone furoate 0.1% |
|
03.03.02 |
Montelukast Singulair® |
|
04.07.02 |
Morphine Salts |
Standard relase (~4 hours effect): Oral solution (e.g. Oramorph®), Tablet (Sevredol®)
Slow release (~12hr effect): Modified Release Capsule: Zormorph and Morphgesic SR. Modified release tablet: MST Continous® Tablet MR
Injection
Morphine Sulphate MR Sachets, Suppositories
|
05.01.12 |
Moxifloxacin |
Tablets
Injection |
11.03.01 |
Moxifloxacin |
0.5% Eye Drops |
02.05.02 |
Moxonidine |
Tablets |
13.10.01.01 |
Mupirocin 2% Bactroban® |
Pre-op indications
|
08.02.01 |
Mycophenolate Mofetil |
|
08.02.01 |
Mycophenolate Sodium Myfortic® |
|
01.05.03 |
Mycophenolate Mofetil |
capsules |
11.08.02 |
Mydricaine |
No 1 Injection
No 2 Injection |
04.06 |
Nabilone |
Capsules |
02.06.04 |
Naftidrofuryl |
Capsules |
01.06.06 |
Naldemedine |
|
04.10.01 |
Nalmefene |
to be initiated and prescribed by commissioned, specialised services. continuation of prescribing needs to be under the advice of commissioned or specialised service |
01.06.06 |
Naloxegol Moventig |
To be used in accordance with NICE TA345 and the constipation pathway
|
15.01.07 |
Naloxone hydrochloride |
400 microgram/ mL injection |
04.10.03 |
Naltrexone Nalorex® |
Tablets
To be prescribed and initiated by specialist service and can be continued to be prescribed under advice or recommendedation of specialist service |
06.04.03 |
Nandrolone Deca-Durabolin® |
injection |
10.01.01 |
Naproxen |
Tablet |
08.02.04 |
Natalizumab Tysabri® |
injection |
02.04 |
Nebivolol |

|
03.03.01 |
Nedocromil Tilade® CFC-free inhaler |
|
04.07.01 |
Nefopam |
Approved only for short-term use by specialist doctor/ consultant in ICU in patients with renal or liver impairment where NSAIDs are contraindicated. |
08.01.03 |
Nelarabine Atriance® |
Intravenous Infusion |
11.04.02 |
Neodocromil Rapitil® |
Sodium Eye Drops 2% |
05.01.04 |
Neomycin |
Tablets, Syrup
Specialist initiation only |
10.02.01 |
Neostigmine |
injection Tablets |
15.01.06 |
Neostigmine Metisulfate |
2.5mg in 1mL injection |
11.04.02 |
Nepafenac |
0.1% Eye Drops |
08.01.05 |
Neratinib |
Approved for use in line with NICE TA612 |
05.03.01 |
Nevirapine Viramune® |
Tablet, Suspension, Tablet MR |
02.06.03 |
Nicorandil |
Tablets
- Not to be used as first-line treatment for angina in line with NICE and MHRA guidance.
- See recent warnings regarding risk of serious skin, mucosal, and eye ulceration, which persists unless treatment is discontinued.
|
02.06.02 |
Nifedipine |
Capsules
Modified Release Tablets to be prescribed by Brand. |
08.01.05 |
Nilotinib Tasigna® |
|
02.06.02 |
Nimodipine Nimotop® |
Tablets and Injection |
03.11 |
Nintedanib Ofev® |
|
08.01.05 |
Nintedanib Vargatef ® |
Tablet |
08.02.04 |
Niraparib (Zejula®) |
Capsule |
04.01.01 |
Nitrazepam |
tablets |
05.01.13 |
Nitrofurantoin |
Tablets, Capsules, Modified Release Capsules, Suspension
1st line for simple cystitis |
08.02.04 |
Nivolumab Opdivo® |
|
02.07.02 |
Noradrenaline / Norepinephrine |
injection |
06.04.01.02 |
Norethisterone |
Tablets |
07.03.02.01 |
Norethisterone |
Tablets |
04.03.01 |
Nortriptyline |
Tablets |
13.02.01 |
Nutraplus Cream |
|
05.02 |
Nystatin Nystan® |
Oral suspension 100 000 units per mL |
13.10.02 |
Nystatin cream |
|
01.09.01 |
Obeticholic acid Ocaliva® |
|
08.02.03 |
Obinutuzumab Gazyvaro ® |
infusion |
08.02.03 |
Ocrelizumab Ocrevus® |
Infusion |
11.08.02 |
Ocriplasmin |
2.5mg/ml Intravitreal Injection |
02.11 |
Octocog alfa sucrose plasma protein-free Iblias® |
|
08.03.04.03 |
Octreotide Sandostatin® |
injection |
08.03.04.03 |
Octreotide Sandostatin Lar® |
50 mcg/ml, 100 mcg/ml injection |
06.04.01.01 |
Oestrogen only HRT gel estradiol Gel |
Estradiol gel |
06.04.01.01 |
Oestrogen only HRT implant Estradiol |
50mg, 100mg Implants
|
06.04.01.01 |
Oestrogens for HRT Estradiol |
Estradiol Tablets 1mg 2mg |
06.04.01.01 |
Oestrogens for HRT Estraderm MX® |
Estraderm MX 25, 50, 75 |
06.04.01.01 |
Oestrogens gel Estradiol® |
gel |
07.02.01 |
Oestrogens, Topical |
Estriol Intra Vaginal Cream 0.01% Contains Arachis (peanut) Oil
Estriol Intra Vaginal Cream 0.1%
|
07.02.01 |
Oestrogens, Topical Vagifem® |
Vaginal tablet: estradiol 10micrograms |
08.02.03 |
Ofatumumab Arzerra® |
Infusion |
05.01.12 |
Ofloxacin |
Tablet "Restricted by Indication" - see list in Antibiotic guidelines
Second line sometimes used for epididymitis/ orchitis as better tolerated |
11.03.01 |
Ofloxacin Eye drops |
Eye Drops 0.3% |
04.02.01 |
Olanzapine |
tablets |
04.02.02 |
Olanzapine Embonate ZypAdhera® |
depot Injection |
08.02.04 |
Olaparib Lynparza® |
|
08.01.05 |
Olaratumab Lartruvo® |
Injection |
03.01.01.01 |
Olodaterol Striverdi Respimat® |
|
11.04.02 |
Olopatadine Opatanol® |
Eye Drops 0.1% |
01.05.01 |
Olsalazine |
tablets, capsules |
03.04.02 |
Omalizumab |
|
05.03.03.02 |
Ombitasvir/ paritaprevir/ ritonavir Viekirax® |
tablet |
01.03.05 |
Omeprazole |
Capsules
orodispersible tablets available for when the beads in the capsule are too large and lansoprazole orodispersible are not acceptable
Injection/ infusion
|
04.06 |
Ondansetron |
Tablets
Injection |
07.03.02 |
Oral Progestogen-Only Contraceptives Femulen® |
Tablet |
09.02.01.02 |
Oral Rehydration Salts Dioralyte® Electrolade |
A prescription should not usually be issued for the treatment of acute diarrhoea in adults, instead self-care should be recommended. NHSE Guidance: OTC items |
04.05.01 |
Orlistat |
Capsules |
05.03.04 |
Oseltamivir Tamiflu® |
Capsule and suspension
To be used with Public health Guidance |
08.02.04 |
Osimertinib Tagrisso |
|
08.01.05 |
Oxaliplatin Eloxatin® |
|
08.01.05 |
Oxaliplatin |
Injection |
04.01.02 |
Oxazepam |
tablets |
04.08.01 |
Oxcarbazepine Trileptal® |
Tablets |
11.07 |
Oxybuprocaine |
0.4% Minims |
07.04.02 |
Oxybutynin |
Tablet Tablet m/r
Information on restriction
Liquid restriced to indication and paediatric use |
07.04.02 |
Oxybutynin Hydrochloride Kentera® |
Patch |
04.07.02 |
Oxycodone |
Liquid
MR Tablets
Capsules
Injection
|
06.04.03 |
Oxymetholone ® |
unlicensed
Tablets |
09.01.03 |
Oxymetholone |
|
05.01.03 |
Oxytetracycline |
Tablets |
07.01.01 |
Oxytocin Syntocinon® |
injection |
08.01.05 |
Paclitaxel |
Injection |
08.01.05 |
Paclitaxel - Albumin Bound Formulation Abraxane® |
Intravenous Infusion |
04.02.02 |
Paliperidone |
Depot Injection |
05.03.05 |
Palivizumab Synagis® |
Injection |
01.09.04 |
Pancreatin Creon® Micro |
Initiated by Paediatric consultant |
01.09.04 |
Pancreatin Pancrex® V |
Tablets Tablets forte Capsule
|
01.09.04 |
Pancreatin Creon® |
Capsules |
15.01.05 |
Pancuronium |
Injection |
08.01.05 |
Panitumumab Vectibix® |
|
08.01.05 |
Panobinostat Farydak® |
tablet |
01.03.05 |
Pantoprazole |
Injection |
04.07.01 |
Paracetamol |
Tablets
Soluble tablets
Suppositories
|
04.07.01 |
Paracetamol |
Intravenous Infusion
Cautionary note: to ensure one checks timing of the previous paracetamol dose before administering the next dose.
Weight considerations ( e.g. >50kg)For patients weighing less than 50kg (use 15mg/kg qds) |
04.07.01 |
Paracetamol Paediatric Solution |
Paracetamol Paediatric Suspension |
04.07.01 |
Paracetamol and codeine Co-codamol® 8/500 |
Tablets,
Capsule
Not to be prescribed by Secondary Care |
04.07.01 |
Paracetamol and codeine Co-codamol ®15/500 |
Tablets
Capsules
Not to be prescribed in Secondary Care |
04.07.01 |
Paracetamol and codeine Co-codamol® 30/500 |
Tablets
Capsules
Not to be prescribed as co-codamol in secondary care |
04.07.01 |
Paracetamol and dihydrocodeine Co-dydramol® |
Not for secondary care prescribing |
04.08.02 |
Paraldehyde |
Injection, Enema. Hospital Only |
04.03.03 |
Paroxetine |
tablets |
08.01.05 |
Pazopanib Votrient® |
Tablet |
08.01 |
Pegaspargase Oncaspar® |
Tablet |
08.02.04 |
Peginterferon Alfa Pegasys® |
|
08.02.04 |
Peginterferon Alfa ViraferonPeg® |
|
08.02.04 |
Peginterferon Beta-1a Plegridy® |
Injection |
08.01.05 |
Pembrolizumab Keytruda® |
infusion |
08.01.03 |
Pemetrexed Alimta® |
Injection |
08.02.04 |
Pemrolizumab Keytruda® |
Infusion |
10.01.03 |
Penicillamine |
|
05.04.08 |
Pentamidine Isetionate Pantacarinat® |
Injection |
08.01.05 |
Pentostatin Nipent® |
Injection |
02.06.04 |
Pentoxifylline Trental® |
Initiated by consultant immunologist for Behcets |
01.02 |
Peppermint Oil |
Capsule |
04.08.01 |
Perampanel Fycompa® |
|
02.05.05.01 |
Perindopril erbumine or tert-butylamine |
tablets |
13.10.04 |
Permethrin Lyclear® |
1% Creme Rinse
5% Cream |
08.01.05 |
Pertuzumab Perjeta® |
Infusion |
04.07.02 |
Pethidine |
Tablets, Injection |
04.03.02 |
Phenelzine Nardil® |
tablets |
02.08.02 |
Phenindione |
|
04.08.01 |
Phenobarbital |
Tablets
Injection
|
01.07.03 |
Phenol, Oily |
injection |
02.05.04 |
Phenoxybenzamine Hydrochloride |
Capsules
Injection |
05.01.01.01 |
Phenoxymethylpenicillin |
Tablets
Syrup |
02.05.04 |
Phentolamine Rogitine®, Regitin® |
injection |
02.07.02 |
Phenylephrine |
|
11.05 |
Phenylephrine |
Minims 2.5%
Minims 10% |
04.08.01 |
Phenytoin Epanutin® |
Injection
Solution for injection |
04.08.01 |
Phenytoin |
Capsule
Oral solution
Tablets |
03.09.01 |
Pholcodine Linctus |
|
09.05.02.01 |
Phosphate Polyfusor ® |
|
09.05.02.01 |
Phosphate supplements Phosphate-Sandoz® |
|
01.06.04 |
Phosphates (Rectal) |
Enema |
09.06.06 |
Phytomenadione Konakion® MM |
|
09.06.06 |
Phytomenadione |
|
09.06.06 |
Phytomenadione Konakion® MM Paediatric |
|
01.06.05 |
Picolax ® |
Oral Sachets |
11.06 |
Pilocarpine |
Eye Drops 1%, 2%, 4%
Minims 1%, 2%, 4% (Hospital Initiated)
Ophthalmic Gel 4% (Hospital Initiated)
|
13.05.03 |
Pimecrolimus 1% Elidel® |
|
06.01.02.03 |
Pioglitazone Actos® |
Tablet |
05.01.01.04 |
Piperacillin and Tazobactam |
Injection
restricted by indication as per the antibiotic guideline
|
04.09.03 |
Piracetam Nootropil® |
Tablets
Oral Solution |
03.11 |
pirfenidone Esbriet® |
|
10.01.01 |
Piroxicam Feldene® |
piroxicam gel |
10.03.02 |
Piroxicam Feldene® |
piroxicam gel |
05.01.01.05 |
Pivmecillinam ® selexid |
Tablets
Group 2 Restricted
For resistant urinary tract infection where no alternative oral agent is suitable. Shown by microbiogical culture and sensitivities |
08.01.02 |
Pixantrone |
|
04.07.04.02 |
Pizotifen |
Tablets |
04.07.04.02 |
Pizotifen |
elixir. Peadiatric consultant initiated only |
09.02.02.02 |
Plasma Expander |
Formulation as per regional cotract |
09.02.02.02 |
Plasma-Lyte® |
|
01.06.05 |
Plenvu plenvu® |
oral powder sachets
Plenvu will be offered as an option when patients are unable to tolerate Moviprep or Picolax, or require restricted fluid intake |
09.01.07 |
Plerixafor Mozobil® |
|
08.01.05 |
Polatuzumab |
|
11.03.01 |
Polyhexamethylene biguanide |
unlicensed
Eye Drops 0.02% |
11.99.99.99 |
Polymyxin B/bacitracin Zinc Polyfax |
Ointment |
09.02.01.01 |
Polystyrene Sulphonate Resins Calcium Resonium® |
|
09.02.01.01 |
Polystyrene Sulphonate Resins Resonium A® |
|
13.09 |
Polytar ® |
|
11.08.01 |
Polyvinyl Alchohol SnoTears® |
Eye Drops 1.4% |
08.02.04 |
Pomalidomide Imnovid® |
|
08.01.05 |
Ponatinib Iclusig® |
|
03.05.02 |
Poractant Alfa Curosurf® |
|
09.02.01.01 |
Potassium Chloride Sando-K® |
12mmol potassium/ dispersible tablet |
09.02.01.01 |
Potassium Chloride Kay-Cee-L® syrup |
1mmol potassium/ 1mL syrup |
09.02.02.01 |
Potassium Chloride + Glucose Intravenous Infusion |
Potassium 0.15% + Glucose 5% (20mmolK+/L) infusion: 500mL,1000mL
Potassium 0.3% + Glucose 5% (40mmolK+/L) infusion: 500mL,1000mL
Potassium 0.15% + Glucose 10% (20mmolK+/L) infusion: 500mL
Potassium 0.3% + Glucose 10% (40mmolK+/L) infusion: 500mL
|
09.02.02.01 |
Potassium Chloride + Sodium Chloride + Glucose Intravenous Infusion |
Potassium 0.15% + Glucose 5% + Sodium Chloride 0.45% (20mmol K+/L) 500mL infusion
Potassium 0.3% + Glucose 5% + Sodium Chloride 0.45% (40mmol K+/L) 500mL infusion
Potassium 0.15% + Glucose 5% +Sodium Chloride 0.9% (20mmol K+/L) 500mL infusion
Potassium 0.3% + Glucose 10% +Sodium Chloride 0.45% (40mmol K+/L) 500mL infusion |
09.02.02.01 |
Potassium Chloride + Sodium Chloride Intravenous |
Potassium 0.15% + Sodium Chloride 0.9% (K+ 20mmol/L) Infusion: 500mL, 1000mL
Potassium 0.3% + Sodium Chloride 0.9% (K+ 40mmol/L) Infusion: 500mL, 1000mL
Potassium 0.6% + Sodium Chloride 0.9% (K+ 80mmol/L) Infusion: 500mL |
09.02.02.01 |
Potassium Chloride 0.6% + Glucose 5% Intravenous |
K+ 80mmol/L |
09.02.02.01 |
Potassium Chloride 15% Injection 10mL ampoule |
Concentrated potassium chloride injection is only stocked in designated areas for use by specialist staff.
|
09.02.02.01 |
Potassium Chloride 7.5% Injection 50mL pre-filled syringe |
High strength pre-filled syringe 7.5% (K+ 1mmol/L) only for use in ITU
|
07.04.03 |
Potassium Citrate |
Potassium Citrate Mixture BP |
13.11.06 |
Potassium Permanganate Permitabs® |
|
04.09.01 |
Pramipexole |
|
02.09 |
Prasugrel Efient® |
|
02.12 |
Pravastatin |
tablets |
05.05.05 |
PRAZIQUANTEL |
unlicensed
Tablet
Unlicensed medicine - named patient use only |
02.05.04 |
Prazosin |
Tablets |
01.05.02 |
Prednisolone |
Rectal Foam Enemas |
01.05.02 |
Prednisolone |
1mg, 2.5mg and 5mg Tablets soluble tablets
enteric coated tablets are for restricted use only . |
06.03.02 |
Prednisolone |
Tablet, soluble tablet, oral solution 5mg/5mL |
11.04.01 |
Prednisolone eye drops |
unlicensed
0.05% Eye Drops
0.1% Eye Drops |
11.04.01 |
Prednisolone eye drops |
Eye Drops 0.5%
Eye Drops 1%
Minims 0.5% |
11.04.01 |
Prednisolone with Neomycin |
Eye Drops |
04.08.01 |
Pregabalin |
capsules
From April 2019 pregabalin will be reclassified as class C controlled substance. Prescriptions will need to be physically signed by doctors; electronic copies will not be accepted by pharmacists - the total quantity will need to be written on the prescription in both words and figures and pharmacists will need to dispense the drugs within 28 days of the prescription being written |
15.02 |
Prilocaine Hydrochloride Citanest® |
1% injection in 50mL |
15.02 |
Prilotekal® |
|
04.08.01 |
Primidone |
Tablets |
10.01.04 |
Probenecid |
tablets |
02.03.02 |
Procainamide |
Injection |
05.01.01.01 |
Procaine Benzylpenicillin |
|
08.01.05 |
Procarbazine |
capsule |
04.06 |
Prochlorperazine |
Tablets, Buccal Tablet, Liquid (Prochlorperazine Maleate)
Injection (Prochlorperazine mesilate)
|
01.07.02 |
Proctosedyl ® |
ointment suppositories |
04.09.02 |
Procyclidine |
Tablets
Procyclidine Injection
|
06.04.01.02 |
Progesterone |
Injection |
06.04.01.02 |
Progesterone pessaries Cyclogest® |
Pessaries
Hospital only Obs and Gynae consultant |
08.02.02 |
Prograf ® |
NHSE funded indication are usually Hospital Only
|
05.04.01 |
Proguanil Hydrochloride Paludrine® |
Tablet For the treatment of malaria Should not be prescribed for malaria prophylaxis on the NHS. Patients should obtain a supply on private prescription or purchase a supply "over the counter" as appropriate |
03.04.01 |
Promethazine |
Tablets, liquid
Injection
|
02.03.02 |
Propafenone |
Tablets
|
11.03.01 |
Propamidine |
Eye Drops 0.1% |
01.02 |
Propantheline |
Tablet For the treatment of hyperhidrosis Also indicated for the treatment of adult enuresis |
07.04.02 |
Propiverine Detrunorm® |
Capsule m/r |
15.01.01 |
Propofol |
10mg/mL injection |
02.04 |
Propranolol |
Tablet
Capsule MR & Liquid
Injection
|
06.02.02 |
Propylthiouracil |
Tablets |
13.02.02 |
Proshield® |
For use in line with the Barrier Products Pathway |
02.08.03 |
Protamine Sulphate |
Injection |
06.05.01 |
Protirelin TRH |
Injection 100 micrograms/ml, 2ml |
11.07 |
Proxymetacaine |
0.5% Minims |
11.07 |
Proxymetacaine with Fluorescein Sodium |
Minims |
01.06.07 |
Prucalopride Resolor® |
To be used in accordance with NICE TA |
05.01.09 |
Pyrazinamide |
tablet
unlicenced - Pyrazinamide Liquid. Consultant Paediatrician Only
|
10.02.01 |
Pyridostigmine Bromide Mestinon® |
tablets |
09.06.02 |
Pyridoxine Hydrochloride |
|
05.04.01 |
Pyrimethamine with Sulfadoxine Fansidar® |
Tablets |
04.02.01 |
Quetiapine |
Tablet, MR tablet - restricted use only, (for patients whome are unable to comply with dosage regimen for standard release formulation) |
06.07.01 |
Quinagolide Norprolac® |
Tablets |
05.04.01 |
Quinine dihydrochloride |
Injection |
05.04.01 |
Quinine Sulfate |
Tablets |
10.02.02 |
Quinine sulphate |
tablets |
13.02.01 |
QV ® Cream |
Only for prescribing when 1st-line emollients have not been effective |
13.02.01 |
QV ® Ointment |
Only for prescribing when 1st-line ointments have not been effective |
01.03.05 |
Rabeprazole |
Tablets |
08.03.04.02 |
Radium-223 dichloride |
|
01.01.02 |
Raft-forming oral suspension Acidex, Acidex Advance, Peptac, |
Prescribe by the most cost-effective brand:
Acidex oral suspension, Peptac® liquid: calcium carbonate 16mg, sodium alginate 50mg, sodium bicarbonate 26.7mg per 1mL
Acidex Advance oral suspension: sodium alginate 100mg, potassium bicarbonate 20mg per 1mL |
06.04.01.01 |
Raloxifene Hydrochloride Evista® |
Tablet |
05.03.01 |
Raltegravir Isentress ® |
Tablet Note: Doses differ according to formulation used and thus tablets and chewable tablets are not equivalent. When prescribing, the formulation must be specified |
08.01.03 |
Raltitrexed Tomudex® |
Infusion |
02.05.05.01 |
Ramipril |
capsule and tablets |
11.08.02 |
Ranibizumab Lucentis® |
Intravitreal Injection |
01.03.01 |
Ranitidine |
Tablets and soluble tablets
Oral solution (Paediatric use)
Injection
|
02.06.03 |
Ranolazine Ranexa® |
Modified Release Tablets
|
04.09.01 |
Rasagiline |
|
10.01.04 |
Rasburicase Fastertec |
injection |
06.03.02 |
Regional emergency box for treatment of inborn errors of metabolism |
Regional emergency box for treatment of inborn errors of metabolism |
08.01.05 |
Regorafenib Stivarga® |
Injection |
15.01.04.03 |
Remifentanil Ultiva® |
Injection
|
06.01.02.03 |
Repaglinide Prandin® |
Tablet |
03.04.02 |
Reslizumab Cinquil® |
Injection |
04.08.01 |
Retigabine |
|
11.08.01 |
Retinol Palimate, WSP, Light LP, LP & Wool Fat |
Eye Ointment |
05.03.05 |
Ribavirin |
Tablet
Capsule |
08.01.05 |
Ribociclib |
Approved for use in line with NICE TA |
05.01.09 |
Rifampicin |
Capsules, Syrup, Injection |
05.01.09 |
Rifampicin and Isoniazid Rifinah® 300 Rifinah® 150 |
tablet |
05.01.09 |
Rifampicin and Isoniazid Rimactazid® 300 |
tablet |
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide Rifater® |
tablet |
05.01.09 |
Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv® |
tablet |
05.01.07 |
Rifaximin |
550mg tablets
Indicated for the prophylaxis of encephalopathy to be used in accordance with NICE TA337 |
05.03.01 |
Rilpivirine hydrochloride Edurant® |
Tablet |
04.09.03 |
Riluzole Rilutek® |
Only Consultant can formerly diagnose and initate the treatment with Riluzole for motor neurone disease |
11.04.01 |
Rimexolone Vexol® |
Eye Drops 1% |
13.05.03 |
Risankizumab |
|
06.06.02 |
Risedronate |
Tablets 35mg |
06.06.02 |
Risedronate |
5mg Tablets |
04.02.01 |
Risperidone |
Tablet
Liquid |
04.02.02 |
Risperidone Risperdal Consta® |
Depot Injection Store in a refrigerator |
05.03.01 |
Ritonavir Norvir® |
Tablet Note: Doses differ according to formulation used and thus tablets and chewable tablets are not equivalent. When prescribing, the formulation must be specified |
08.02.03 |
Rituximab MabThera®Truxima ® |
Injection |
10.01.03 |
Rituximab (rheumatology) MabThera® |
infusion |
02.08.02 |
Rivaroxaban Xarelto® |
Tablets |
04.11 |
Rivastigmine |
Capsules
Patches |
04.07.04.01 |
Rizatriptan Maxalt® |
Tablets |
15.01.05 |
Rocuronium |
Injection |
03.03.03 |
Roflumilast Daxas® |
Tablets
For treating Chronic Obstrustive Pulmonary Disease |
09.01.04 |
Romiplostim Nplate® |
|
04.09.01 |
Ropinirole |
|
15.02 |
Ropivacaine Hydrochloride Naropin® |
|
02.12 |
Rosuvastatin |
Tablets
|
04.09.01 |
Rotigotine |
|
08.01.05 |
Rucaparib |
Approved in line with NICE TA611 |
08.01.05 |
Ruxolitinib Jakavi® |
Tablet |
02.15 |
Sacubitril valsartan Entresto® |
Tablets
Neprilysin Inhibitors with Angiotensin-II Receptor Antagonists
|
03.01.01.01 |
Salbutamol |
CFC Free MDI, Easi-Breathe, DPI, Syrup, Injection, Nebules
|
Short acting beta agonist
- 1st line = MDI + spacer
- 2nd line = CFC free breath actuated (Salamol Easi-Breathe® - prescribe by brand)
- 3rd line = DPI (Easyhaler® Salbutamol)NB Device expires 6 months after the foil pouch is opened
- Nebules also available. Nebs may be diluted with 0.9% sodium chloride if needed
|
Salbutamol Tablets are Hopital only
Salbutamol 200mcg DPI is non formulary
|
07.01.03 |
Salbutamol |
Injection
Please refere chapter 3, section 3.1.1.1 for respiratory use |
09.05.01.01 |
Sandocal 1000 ® |
Calcium carbonate with calcium lactate gluconate |
05.03.01 |
Saquinavir Invirase® |
Tablet |
10.01.03 |
Sarilumab (Kevzara®) |
Injection - prefilled syringe of pen |
06.01.02.03 |
Saxagliptin Onglyza® |
Tablet |
01.07.02 |
Scheriproct ® ointment |
Ointment Supositories |
13.05.02 |
Sebco ® scalp ointment |
|
10.01.03 |
Secukinumab |
Injection - syringe or pre-filled pen. |
13.05.03 |
Secukinumab |
|
04.09.01 |
Selegiline Hydrochloride |
|
06.01.02.03 |
Semaglutide Ozempic® |
Injection
To be used as combination therapy |
01.06.02 |
Senna |
Tablets, Syrup
|
04.03.03 |
Sertraline |
Tablet |
15.01.02 |
Sevoflurane |
250mL bottle for vaporisation |
07.04.05 |
Sildenafil |
Tablet Prescribers should ensure that generic sildenafil tablets are used as the first line PDE5 inhibitor of choice |
13.10.01.01 |
Silver Sulfadiazine Flamazine® |
|
11.08.01 |
Simple Eye Ointment |
|
03.09.02 |
Simple Linctus |
|
03.09.02 |
Simple Linctus, Paediatric BP |
|
02.12 |
Simvastatin |
Tablets |
08.02.04 |
Siponimod |
|
08.02.02 |
Sirolimus Rapamune® |
|
06.01.02.03 |
Sitagliptin Januvia® |
Tablet |
07.04.03 |
Sodium Bicarbonate |
|
09.02.01.03 |
Sodium Bicarbonate |
500mg capsules |
09.02.02.01 |
Sodium Bicarbonate |
Intravenous infusion 1.26%, 500mL Polyfusor®
Intravenous infusion 1.4%, 500mL Polyfusor®
Intravenous infusion 4.2%, 500mL Polyfusor®
Intravenous injection 4.2% 10mL
Intravenous infusion 8.4% 200mL Polyfusor®
Intravenous injection 8.4% 50mL Minjet
Intravenous injection 8.4% 10mL |
09.02.01.02 |
Sodium Chloride Slow Sodium® |
|
11.08.01 |
Sodium Chloride |
Eyes Drops 0.9%
Minims 0.9%
Eye Drops 5% (Hospital initiated for at least 1st 3 months)
|
03.07 |
Sodium chloride 3%, 6% (Hypertonic) MucoClear® |
Nebules |
09.02.02.01 |
Sodium Chloride Intravenous |
Sodium Chloride 0.18% 500mL infusion
Sodium Chloride 0.45% 500mL infusion
Sodium Chloride 0.9% 50mL, 100mL, 250mL, 1000mL infusion
Sodium Chloride 0.9% 2mL, 5mL, 10mL, 20mL ampoules
Sodium Chloride 0.9% irrigation
Sodium Chloride 1.8% 500mL infusion
Sodium Chloride 2.7% 500mL infusion
|
01.01.02 |
Sodium citrate 0.3M |
|
06.06.02 |
Sodium Clodronate |
400mg capsules |
01.05.04 |
Sodium cromoglicate Nalcrom® |
100mg capsules |
03.03.01 |
Sodium Cromoglicate |
MDI |
11.04.02 |
Sodium Cromoglicate |
Eye Drops 2% |
09.01.01.01 |
Sodium Feredetate |
|
05.01.07 |
Sodium fusidate |
Tablet, Suspension, Infusion Microbiologist approval required in all cases |
11.08.01 |
Sodium Hyaluronate |
Syringe
0.4% Preservative Free Eye Drops Unit Dose |
02.05.01 |
Sodium nitroprusside |
Injection |
01.06.02 |
Sodium Picosulfate |
Liquid Sachets |
04.02.03 |
Sodium valproate |
tablets |
04.08.01 |
Sodium Valproate Epilim® |
Standard-release and modified-release oral dosage forms |
04.08.01 |
Sodium Valproate Epilim® Intravenous |
intravenous injection |
05.03.03.02 |
Sofosbuvir Sovaldi® |
Tablet |
05.03.03.02 |
Sofosbuvir, Velpatasvir and Voxilaprevir Vosevi® |
Tablet |
07.04.02 |
Solifenacin Vesicare® |
Tablet |
06.05.01 |
Somatropin Omnitrope® Humatrope® genotropin® and Zomacton® |
The seven manufacturers have UK marketing authorisations for somatropin for the following indications:
Lilly (Humatrope): Growth hormone deficiency; Turner syndrome; CRI, short children born small for gestational age and SHOX deficiency
Ferring ( Zomacton): Growth Hormone deficiency and turner syndrome
Ipsen (NutropinAq): Growth hormone deficiency; Turner syndrome and CRI
Novo Nordisk (Norditropin SimpleXx): Growth Hormone deficiency; Turner syndrome; CRI and short children born small for gestation age
Pfizer (Genotropin): Growth hormone deficiency; Turner syndrome; CRI;Prader-Willi syndrome and short children born small for gestational age
Sandoz (Omnitrope): Growth Hormone deficiency; Turner syndrome;CRI; Prader-Willi syndrome and short children born small for gestational age
Merck Serono (Saizen): Growth Hormone deficiency; Turner syndrome; CRI and short children born small for gestational age |
08.01.05 |
Sorafenib Nexavar® |
Tablet |
02.04 |
Sotalol |
Tablet |
05.01.07 |
Spectinomycin |
Centre for Sexual Health Only |
02.02.03 |
Spironolactone |
FIRST CHOICE |
05.03.01 |
Stavudine Zerit® |
Capsule, Oral Solution |
02.10.02 |
Streptokinase |
injection |
05.01.09 |
Streptomycin Sulphate |
Injection |
09.02.02.02 |
Succinylated Gelatin Gelaspan® |
|
01.03.03 |
Sucralfate |
Tablets and Suspension |
01.03.03 |
Sucralfate |
Enema
Unlicenced formulation |
15.01.06 |
Sugammadex |
|
05.01.08 |
Sulfadiazine |
Tablets |
01.05.01 |
Sulfasalazine salazopyrin |
Tablets, Suspension |
10.01.03 |
Sulfasalazine EC Salazopyrin EN-Tabs® |
tablet |
04.07.04.01 |
Sumatriptan |
Tablets
Sumatriptan Nasal Spray. Paediatric Consultant Initiated
Sumatriptan Injection. *for migraine and cluster headaches*
|
08.01.05 |
Sunitinib Sutent® |
Capsule |
09.03 |
Supplementary Preparations Additrace® |
|
09.03 |
Supplementary Preparations Peditrace® |
|
09.03 |
Supplementary Preparations Solivito N® |
|
09.03 |
Supplementary Preparations Vitlipid N® |
|
15.01.05 |
Suxamethonium |
Injection |
13.05.02 |
Tacalcitol |
|
13.05.03 |
Tacrolimus Protopic® |
|
07.04.05 |
Tadalafil Cialis® |
Tablets 10mg, 20mg |
08.02.04 |
Talimogene laherparepvac Imlygic® |
injection |
08.01.05 |
Talimogene laherparepvec Imlygic® |
|
08.03.04.01 |
Tamoxifen |
Tablets 10mg, 20mg. |
07.04.01 |
Tamsulosin |
Modified Release tablets
Modified Release Capsules |
04.07.02 |
Tapentadol Palexia® |
Modified release tablets |
05.01.07 |
Tedizolid Sivextro® |
200mg Tablets, Infusion
Microbiology Approval is requires in all cases |
08.01.03 |
Tegafur with Uracil Uftoral® |
Capsule |
05.01.07 |
Teicoplanin |
Injection |
05.03.03.02 |
Telaprevir Incivo® |
Tablet |
04.01.01 |
Temazepam |
Tablets, oral solution |
05.01.01.02 |
Temocillin |
Injection
Restricted use only requiring microbiologist approval in all cases |
08.01.05 |
Temozolomide Temodal® |
capsule |
08.01.05 |
Temsirolimus Torisel® |
infusion |
02.10.02 |
Tenecteplase Metalyse® |
|
05.03.01 |
Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla® |
Tablet |
05.03.01 |
Tenofovir alafenamide, elvitegravir, cobicistat & emtricitabine Genvoya® |
Tablet Restricted to use in accordance with the NHS England commissioning guidance |
05.03.01 |
Tenofovir and Emtricitabine Truvada® |
Tablet |
05.03.01 |
Tenofovir Disproxil Viread® |
Tablet |
05.03.01 |
Tenofovir, cobicistat, elvitegravir & emtricitabine Stribild® |
Tablet Restricted to use in accordance with the NHS England commissioning guidance. |
05.02 |
Terbinafine |
Tablet |
05.02 |
Terbinafine Lamisil® |
Terbinafine hydrochloride 1%
Topical preparation, please consult chapter 13 for further information |
13.10.02 |
Terbinafine 1% cream |
|
03.01.01.01 |
Terbutaline |
DPI, Respirator Solution, Respules (2ml)
|
- Short-acting beta-agonist
- Turbohaler and Respules available
- Limited use where patient intolerant of salbutamol and in those patients whose condition is exacerbated by an aerosol
|
|
08.02.04 |
Teriflunomide Aubagio® |
|
06.06.01 |
Teriparatide Forsteo ® |
Injection |
06.05.02 |
Terlipressin Glypressin® |
Injection 1mg Vial |
06.04.02 |
Testosterone |

300micrograms/24hour patch |
06.04.02 |
Testosterone gel Tostran® |
Gel 2% |
06.04.02 |
Testosterone implant |
Implant |
06.04.02 |
Testosterone undecanoate Nebido® |
Intramuscular Injection |
04.09.03 |
Tetrabenazine Xenazine® 25 |
Tablets |
11.07 |
Tetracaine |
Eye Drops 1% |
15.02 |
Tetracaine Ametop® |
|
06.05.01 |
Tetracosactide Synacthen® |
Injection
Available as:
Short Synacthen test 250mcg (IM/IV)
Depot for prolonged synacthen 1mg IM |
08.02.04 |
Thalidomide Celgene® |
|
03.01.03 |
Theophylline |
Modified Release Tablet
Theophylline has a narrow therapeutic index and troublesome interactions (especially with macrolides & nicotine). N.B. PRESCRIBE BY BRAND - Be aware that oral modified release brands of theophylline and aminophylline are NOT interchangeable. All patients need to be maintained on the same brand as initally prescribed for them.
Liquid ( Unlicensed, specials )
|
09.06.02 |
Thiamine |
|
15.01.01 |
Thiopental sodium |
500mg injection |
08.01.01 |
Thiotepa |
Injection |
11.08.02 |
Thymoxamine Moxisylyte ® |
Eye Drops |
05.05.07 |
TIABENDAZOLE |
Tablets |
06.04.01.01 |
Tibolone Livial® |
2.5mg tablets |
02.09 |
Ticagrelor Brilique® |
|
05.01.01.04 |
Ticarcillin |
Injection
Group 3 restricted
|
05.01.07 |
Tigecycline |
Injection Microbiologist approval required in all cases |
13.05.03 |
Tildrakizumab |
|
11.06 |
Timolol |
Eye Drops 0.25%
Eye Drops 0.5%
LA Eye Drops 0.25%
LA Eye Drops 0.5%
Single Dose Eye Drops 0.25%
Single Dose Eye Drops 0.5% |
02.08.01 |
Tinzaparin |
|
08.01.03 |
Tioguanine Lanvis® |
Tablet |
03.01.02 |
Tiotropium |
For COPD
- Prescribe by brand.
- Despite being different doses; Braltus® and Spiriva® Handihaler and Respimat are clinically equivalent and produce the same amount of active ingredient in the body. 10 micrograms of Braltus® is equivalent to 18 micrograms of Spiriva® Handihaler and 5 micrograms of Respimat.
- Capsules for Spiriva® Handihaler and Braltus® should be used for their intended device only.
- Spiriva® should be prescribed/endorsed with the type of device intended on the prescription (either HandiHaler or Respimat).
- The Braltus Zonda is significantly cheaper than Spiriva HandiHaler and product switching from the Spiriva product to Braltus Zonda is encouraged.
For Asthma
- Only the Respimat® device is licensed for asthma
|
03.01.04 |
Tiotropium & olodaterol ® Spiolto Respimat |
|
02.09 |
Tirofiban Aggrastat® |
INJECTION |
08.01.05 |
Tivozanib (Fotivda®) |
Capsule |
10.02.02 |
Tizanidine Zanaflex® |
|
05.01.04 |
Tobramycin |
nebuliser solution |
05.01.04 |
Tobramycin |
Injection
|
05.01.04 |
Tobramycin inhaler TOBI Podhaler® |
Inhaler |
10.01.03 |
Tocilizumab RoActemra® |
infusion |
10.01.03 |
Tofacitinib (Xeljanz®) |
Tablet |
02.05.01 |
Tolazoline |
Injection.
Hospital, Paediatrics Only
|
07.04.02 |
Tolterodine |
Tablet
Information on restriction
Capsule M/R Modified Release Capsule are restricted |
06.05.02 |
Tolvaptan Jinarc® |
Tablets |
04.08.01 |
Topiramate |
Tablets
Hard capsules |
08.01.05 |
Topotecan Hycamtin® |
Capsule and Injection |
08.03.04.01 |
Toremifene Fareston® |
Tablets 60mg |
08.01.05 |
Trabectedin Yondelis® |
Injection |
04.07.02 |
Tramadol |
Capsules
Tablets
Injection
|
08.01.05 |
Trametinib Mekinist® |
Tablet |
02.11 |
Tranexamic Acid |
Tablets
injection |
08.01.05 |
Trastuzumab Herceptin® |
Injection |
08.01.05 |
Trastuzumab emtansine Kadcyla® |
Infusion |
11.06 |
Travoprost |
Eye Drops 40mcg/ml |
11.06 |
Travoprost with Timolol |
Eye Drops Travoprost 40mcg/ml with Timolol 5mg/ml |
04.03.01 |
Trazodone |
Capsule,
Tablet
Liquid |
08.01.01 |
Treosulfan |
|
08.01.05 |
Tretinoin Vesanoid® |
Capsule |
10.01.02.02 |
Triamcinolone Acetonide Adcortyl® |
|
10.01.02.02 |
Triamcinolone Acetonide Kenalog® |
|
04.02.01 |
Trifluoperazine |
Tablet
Oral solution |
08.01.05 |
Trifluridine and Tipiracil Lonsurf ® |
Tablet |
04.09.02 |
Trihexyphenidyl (Benzhexol) |
Tablets |
05.01.08 |
Trimethoprim |
Tablets, Suspension
Injection
|
05.01.13 |
Trimethoprim |
|
06.07.02 |
Triptorelin Gonapeptyl Depot® |
Injection |
08.03.04.02 |
Triptorelin Decapeptyl® |
Injection |
11.05 |
Tropicamide |
Eye Drops 0.5%
Eye Drop 1%
|
11.05 |
Tropicamide 0.28 mg and Phenylephrine hydrochloride 5.4 mg Mydriasert® |
|
11.05 |
Tropicamide Minims |
Minims 0.5%
Minims 1% |
07.04.02 |
Trospium |
Tablets 20mg, 60mg MR Capsules. As Per APC OAB Pathway |
06.07.02 |
Ulipristal Esmya® |
License suspended March 2020: MHRA update
As per MHRA Alert Do not initiate or re-start treatment; monitor liver function in current and recent users **
|
07.03.05 |
Ulipristal EllaOne® |
Tablet |
13.02.01 |
Ultrabase® Ointment |
|
03.01.02 |
Umeclidinium Incruse Ellipta® |
|
03.01.04 |
Umeclidinium & vilanterol Anoro Ellipta® |
|
02.10.02 |
Urokinase |
injection
|
01.09.01 |
Ursodeoxycholic acid |
capsules suspension |
01.05.03 |
Ustekinumab Stelera ® |
|
10.01.03 |
Ustekinumab |
Injection |
13.05.03 |
Ustekinumab |
|
05.03.02.01 |
Valaciclovir Valtrex® |
Tablets
*Only to be prescribed on advice of microbiologist. Indication for treatment of HSV PCR Positive viral meningitis ( not for encephalitis for which iv aciclovir must be used)* |
05.03.02.02 |
Valganciclovir Valcyte® |
Tablet, Oral solution
Prevention of cytomegalovirus disease following solid organ transplantion. Complete course should be provided from transplant centre - not funded for prescribing in primary care |
04.02.03 |
Valproic Acid Depakote® |
Tablet |
02.05.05.02 |
Valsartan |
Capsules, Tablets |
05.01.07 |
Vancomycin |
Capsules
|
05.01.07 |
Vancomycin |
Injection |
07.04.05 |
Vardenafil Levitra® |
Tablets |
04.10.02 |
Varenicline Champix® |
tablets
To be prescribed and initiated by specialised service |
06.05.02 |
Vasopressin Pitressin® |
A Argipressin
Injection |
15.01.05 |
Vecuronium |
Injection |
01.05.03 |
Vedolizumab |
to be used in accordance with NICE TA352 and NICE TA342 |
13.08.02 |
Veil ® |
ACBS preparation which can only be prescribed for disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitilgo) |
08.01.05 |
Vemurafenib Zelboraf® |
Tablets |
08.01.05 |
Vemurafenib (Zelboraf® ) |
tablet |
08.01.05 |
Venetoclax Venclyxto ® |
Tablet |
04.03.04 |
Venlafaxine |
Tablet, Capsule MR, Tablet MR
Note :
There has been a price change in the XL formulation and the 225mg strength is relatively costly. Hence the recommendation is not to prescribe 225mg tablets, but to prescribe the others strengths in order to achieve the dose required |
02.06.02 |
Verapamil |
Tablets and Modified Release Tablets
verapamil Injection
|
11.08.02 |
Verteporfin Visudyne® |
Injection |
08.01.04 |
Vinblastine Sulphate |
Injection |
08.01.04 |
Vincristine Sulphate |
injection |
08.01.04 |
Vindesine Sulphate Eldisine® |
injection |
08.01.04 |
Vinorelbine |
Injection, capsule |
09.06.02 |
Vitamin B Tablets, Compound Strong |
Only approved for re-feeding syndrome.
Vitamin B supplementation should not be prescribed for the prevention of Wernicke's Encephalopathy in alcholism |
05.02 |
Voriconazole Vfend® |
Tablets, Injection |
11.03.02 |
Voriconazole |
unlicensed
1% Eye Drops |
04.03.03 |
Vortioxetine |
Tablets |
08.01.05 |
Vosaroxin Qinprezo |
Injection |
02.08.02 |
Warfarin |
Tablets |
09.02.02.01 |
Water for Injection |
2mL, 5mL, 10mL, 20mL |
11.08.01 |
White Soft Paraffin 57.3%, Liquid Paraffin 42.5% |
Eye Ointment |
13.02.01 |
White Soft Paraffin BP |
|
01.07.02 |
Xyloproct ® |
ointment |
03.03.02 |
Zafirlukast |
|
05.03.04 |
Zanamivir Dectova® |
Consultant microbiologist authorisation only |
05.03.04 |
Zanamivir inhalation Relenza® |
|
13.02.01 |
Zerobase ® gel |
|
13.02.01 |
Zerocream ® |
|
13.02.01 |
Zeroderm ® Ointment |
|
13.02.01 |
Zerodouble ® Gel |
|
05.03.01 |
Zidovudine Retrovir® |
Capsule |
05.03.01 |
Zidovudine and Lamivudine Combivir® |
Tablet |
13.02.02 |
Zinc and Castor Oil Cream 15% |
|
09.05.04 |
Zinc Sulphate Solvazinc® |
|
06.06.02 |
Zoledronic Acid Aclasta® |
5mg Intravenous Infusion |
06.06.02 |
Zoledronic Acid Zometa® |
4mg Intravenous Infusion |
04.01.01 |
Zolpidem |
Tablets |
04.08.01 |
Zonisamide Zonegran® |
Capsules |
04.01.01 |
Zopiclone |
|
04.02.01 |
Zuclopenthixol Clopixol® |
Tablet |
04.02.01 |
Zuclopenthixol Acetate Clopixol Acuphase® |
Zuclopenthixol Acetate (acuphase) |
04.02.02 |
Zuclopenthixol Decanoate Clopixol® |
Depot Injection |